

CITATION REPORT

List of articles citing

Patient-derived tumour xenografts as models for oncology drug development

DOI: 10.1038/nrclinonc.2012.61

Nature Reviews Clinical Oncology, 2012, 9, 338-50.

Source: <https://exaly.com/paper-pdf/53995350/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1019	Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx). 2012 , 4, 821-45		34
1018	BAY 1000394, a novel cyclin-dependent kinase inhibitor, with potent antitumor activity in mono- and in combination treatment upon oral application. 2012 , 11, 2265-73		98
1017	Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. 2012 , 18, 6658-67		125
1016	Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. 2012 , 17, 229-39		30
1015	Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. 2013 , 11, 168		63
1014	A multi-site feasibility study for personalized medicine in canines with osteosarcoma. 2013 , 11, 158		12
1013	Origin of the vasculature supporting growth of primary patient tumor xenografts. 2013 , 11, 110		55
1012	Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung cancer. 2013 , 12, 16		37
1011	Luminal breast cancer: from biology to treatment. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 494-506	19.4	123
1010	Patient-derived xenografts, the cancer stem cell paradigm, and cancer pathobiology in the 21st century. 2013 , 93, 970-82		153
1009	Discovery of novel drugs for promising targets. 2013 , 35, 1271-81		11
1008	Tumor-derived hydrogen sulfide, produced by cystathionine- β -synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. 2013 , 110, 12474-9		441
1007	Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastasis. 2013 , 22 Suppl 2, S57-65		35
1006	Humanised xenograft models of bone metastasis revisited: novel insights into species-specific mechanisms of cancer cell osteotropism. 2013 , 32, 129-45		40
1005	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. 2013 , 7, 776-90		116
1004	Genetically engineered mouse models of PI3K signaling in breast cancer. 2013 , 7, 146-64		28
1003	Pharmacokinetics and pharmacodynamics of sunitinib for the treatment of advanced pancreatic neuroendocrine tumors. 2013 , 9, 777-88		5

1002	A bioengineered heterotypic stroma-cancer microenvironment model to study pancreatic ductal adenocarcinoma. 2013 , 13, 3965-75	43
1001	Molecular characterization of patient-derived human pancreatic tumor xenograft models for preclinical and translational development of cancer therapeutics. 2013 , 15, 1138-50	71
1000	Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer. 2013 , 182, 227-34	15
999	Translating metastasis-related biomarkers to the clinic--progress and pitfalls. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 169-79	19.4 35
998	New perspectives on molecular targeted therapy in ovarian clear cell carcinoma. 2013 , 108, 1553-9	71
997	Primary human non-small cell lung and pancreatic tumorgraft models--utility and applications in drug discovery and tumor biology. 2013 , Chapter 14, Unit 14.26	15
996	Measuring activity in the ubiquitin-proteasome system: from large scale discoveries to single cells analysis. 2013 , 67, 75-89	16
995	Mouse models for liver cancer. 2013 , 7, 206-23	121
994	A short-term colorectal cancer sphere culture as a relevant tool for human cancer biology investigation. 2013 , 108, 1720-31	36
993	Designing transformative clinical trials in the cancer genome era. 2013 , 31, 1834-41	135
992	Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. 2013 , 19, 4149-62	58
991	An integrated approach to identifying clinically relevant targets in pediatric gliomas. 2013 , 2, 303-6	0
990	Xenograft tumors vascularized with murine blood vessels may overestimate the effect of anti-tumor drugs: a pilot study. 2013 , 8, e84236	14
989	Current status and evolution of preclinical drug development models of epithelial ovarian cancer. 2013 , 3, 296	29
988	Carcinoma-associated fibroblasts are a promising therapeutic target. 2013 , 5, 149-69	110
987	From bench to bedside: does preclinical practice in translational oncology need some rebuilding?. 2013 , 105, 1426-7	12
986	The microenvironment and resistance to personalized cancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10,	19.4 20
985	Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. 2013 , 18, 1180-8	19

984	Patient-derived tumor xenograft model to guide the use of BRAF inhibitors in metastatic melanoma. 2013 , 23, 373-80	11
983	ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. 2013 , 12, 1131-9	27
982	Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. 2013 , 73, 3381-92	73
981	Formalizing an integrative, multidisciplinary cancer therapy discovery workflow. 2013 , 73, 6111-7	17
980	Metastatic castration-resistant prostate cancer hungers for leucine. 2013 , 105, 1427-8	1
979	Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. 2013 , 3, 295	80
978	Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. 2013 , 19, 6219-29	45
977	Cancer of mice and men: old twists and new tails. 2013 , 230, 4-16	2
976	A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. 2013 , 73, 4885-97	331
975	From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. 2013 , 105, 1441-56	41
974	The in ovo CAM-assay as a xenograft model for sarcoma. 2013 , e50522	36
973	Personalised Cancer Medicine: Fulfilling the Promise. 2013 ,	1
972	Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation. 2013 , 8, e67258	27
971	Selecting the best drugs for phase I clinical development and beyond. 2013 , 469-73	3
970	Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma. 2014 , 9, e89474	40
969	Genomic characterisation of small cell lung cancer patient-derived xenografts generated from endobronchial ultrasound-guided transbronchial needle aspiration specimens. 2014 , 9, e106862	28
968	"Glowing head" mice: a genetic tool enabling reliable preclinical image-based evaluation of cancers in immunocompetent allografts. 2014 , 9, e109956	20
967	Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. 2014 , 9, e113037	33

966	Human tumor xenograft models for preclinical assessment of anticancer drug development. 2014 , 30, 1-5	73
965	. 2014 ,	0
964	KRAS and PIK3CA Mutation Frequencies in Patient-derived Xenograft Models of Pancreatic and Colorectal Cancer Are Reflective of Patient Tumors and Stable Across Passages. 2014 , 80, 873-877	21
963	Patient-derived xenograft models in gynecologic malignancies. 2014 , e258-66	31
962	Mouse models of mesothelioma: strengths, limitations and clinical translation. 2014 , 3, 397-410	7
961	Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics. 2014 , 6, 116	22
960	A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia. 2014 , 4, e232	23
959	Targeting the c-Met/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas. 2014 , 74, 7546-59	75
958	Use of rodents as models of human diseases. 2014 , 6, 2-9	176
957	Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer. 2014 , 4, 322	10
956	Response to MLN8237 in pancreatic cancer is not dependent on RalA phosphorylation. 2014 , 13, 122-33	15
955	Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. 2014 , 5, 5469	67
954	Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma. 2014 , 232, 386-90	51
953	Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. 2014 , 74, 6980-90	89
952	Lessons from patient-derived xenografts for better in vitro modeling of human cancer. 2014 , 79-80, 222-37	126
951	Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer. 2014 , 13, 1636-44	43
950	Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings. 2014 , 14, 178	19
949	Genomic profiling of patient-derived colon cancer xenograft models. 2014 , 93, e298	14

948	Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. 2014 , 13, 1537-48	151
947	Patient-derived tumour xenografts as models for breast cancer drug development. 2014 , 26, 556-61	31
946	Nuclear Signaling Pathways and Targeting Transcription in Cancer. 2014 ,	3
945	Developments in preclinical cancer imaging: innovating the discovery of therapeutics. 2014 , 14, 314-28	112
944	Oncology drug discovery: planning a turnaround. 2014 , 4, 397-404	41
943	Cancer cell lines for drug discovery and development. 2014 , 74, 2377-84	234
942	Implications of intratumour heterogeneity for treatment stratification. 2014 , 232, 264-73	52
941	Circulating tumor cells: a multifunctional biomarker. 2014 , 20, 2553-68	151
940	Cancer as a metabolic disease: implications for novel therapeutics. 2014 , 35, 515-27	263
939	The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. 2014 , 69-70, 42-51	234
938	An 'in-cell trial' to assess the efficacy of a monovalent anti-MET antibody as monotherapy and in association with standard cytotoxics. 2014 , 8, 378-88	6
937	Molecularly targeted cancer therapy: some lessons from the past decade. 2014 , 35, 41-50	206
936	One mouse, one patient paradigm: New avatars of personalized cancer therapy. 2014 , 344, 1-12	218
935	Modeling human carcinomas: physiologically relevant 3D models to improve anti-cancer drug development. 2014 , 79-80, 50-67	99
934	Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. 2014 , 63, 1668-76	83
933	Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. 2014 , 94, 917-26	26
932	Patient-derived xenograft models: an emerging platform for translational cancer research. 2014 , 4, 998-1013	1018
931	Translating genomics for precision cancer medicine. 2014 , 15, 395-415	56

930	Three-dimensional cancer models mimic cell-matrix interactions in the tumour microenvironment. 2014 , 35, 1671-9	95
929	Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance. 2014 , 61, 1570-7	19
928	Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening. 2014 , 11, 2040-50	60
927	Biomimetic nanoparticles for siRNA delivery in the treatment of leukaemia. 2014 , 32, 1396-409	31
926	Transcriptional dissection of pancreatic tumors engrafted in mice. 2014 , 6, 27	30
925	A historical perspective of pancreatic cancer mouse models. 2014 , 27, 96-105	19
924	Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance. 2014 , 15, 416	21
923	Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. 2014 , 10, 1065-80	8
922	Modern Cancer Drug Discovery. 2014 , 3-53	5
921	Translational research in oncology--10 years of progress and future prospects. <i>Nature Reviews Clinical Oncology</i> , 2014 , 11, 649-62	19.4 51
920	Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. 2014 , 91, 135-43	129
919	Organoid cultures for the analysis of cancer phenotypes. 2014 , 24, 68-73	211
918	Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation. 2014 , 142, 351-61	26
917	The potential of hyperpolarized (13)C MRI in assessing signaling pathways in cancer. 2014 , 21, 215-22	10
916	Imaging preclinical tumour models: improving translational power. 2014 , 14, 481-93	128
915	An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. 2014 , 74, 1214-26	103
914	Promises and Challenges with Immunomodulatory Biologics. 2014 , 159-188	
913	Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses. 2014 , 61 Suppl 1, 74-83	12

912	Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps. 2015 , 4, 201-11	58
911	The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice. 2015 , 5, 9447	27
910	Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods. 2015 , 5, 14495	31
909	The status of donor cancer tissues affects the fate of patient-derived colorectal cancer xenografts in NOG mice. 2015 , 64, 181-90	4
908	Current State of Animal (Mouse) Modeling in Melanoma Research. 2015 , 8, 81-94	60
907	Bioengineering Models for Breast Cancer Research. 2015 , 9, 57-70	14
906	Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine. 2015 , 7, 608-27	29
905	Genetically modified "obligate" anaerobic Salmonella typhimurium as a therapeutic strategy for neuroblastoma. 2015 , 8, 99	12
904	Imaging Mouse Models of Cancer. 2015 , 21, 152-64	12
903	Cancer Stem Cell and Gastrointestinal Cancer: Current Status, Targeted Therapy and Future Implications. 2016 , 5,	2
902	Establishment of a patient-derived orthotopic Xenograft (PDOX) model of HER-2-positive cervical cancer expressing the clinical metastatic pattern. 2015 , 10, e0117417	90
901	Initiation and characterization of small cell lung cancer patient-derived xenografts from ultrasound-guided transbronchial needle aspirates. 2015 , 10, e0125255	32
900	Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft. 2015 , 10, e0126867	15
899	Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. 2015 , 10, e0134346	56
898	Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. 2015 , 10, e0135220	26
897	Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. 2015 , 135, 842-850	24
896	Prioritizing therapeutic targets using patient-derived xenograft models. 2015 , 1855, 223-34	23
895	Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. 2015 , 21, 4165-73	58

894	Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. 2015 , 185, 1297-303	75
893	A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment. 2015 , 21, 274-83	40
892	Human tumor xenografts in mouse as a model for evaluating therapeutic efficacy of monoclonal antibodies or antibody-drug conjugate targeting receptor tyrosine kinases. 2015 , 1233, 151-9	3
891	Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours. 2015 , 136, E252-61	62
890	Novel insights into head and neck cancer using next-generation "omic" technologies. 2015 , 75, 480-6	42
889	Early phase clinical trials to identify optimal dosing and safety. 2015 , 9, 997-1007	59
888	Reprogramming of human cancer cells to pluripotency for models of cancer progression. 2015 , 34, 739-47	40
887	Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts. 2015 , 75, 303-13	29
886	Evaluating patient-derived colorectal cancer xenografts as preclinical models by comparison with patient clinical data. 2015 , 75, 1560-6	70
885	Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer. 2015 , 13, 42	41
884	Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion. 2015 , 68, 89-99	31
883	Ovarian and cervical cancer patient derived xenografts: The past, present, and future. 2015 , 138, 486-91	34
882	IGF1 Receptor Targeted Theranostic Nanoparticles for Targeted and Image-Guided Therapy of Pancreatic Cancer. 2015 , 9, 7976-91	110
881	Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. 2015 , 33, 2472-80	76
880	Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems. 2015 , 15, 426-39	67
879	A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. 2015 , 29, 1390-401	32
878	A new mouse avatar model of non-small cell lung cancer. 2015 , 5, 52	13
877	Xenotransplantation of cryopreserved human ovarian tissue--a systematic review of MII oocyte maturation and discussion of it as a realistic option for restoring fertility after cancer treatment. 2015 , 103, 1557-65	27

876	Mouse hospital and co-clinical trial project--from bench to bedside. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 491-8	19.4	82
875	Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform. 2015 , 16, 165-72		13
874	Systems biology approaches for advancing the discovery of effective drug combinations. 2015 , 7, 7		79
873	p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. 2015 , 14, 1117-29		28
872	Validation of p27KIP1 expression levels as a candidate predictive biomarker of response to rapalogs in patient-derived breast tumor xenografts. 2015 , 36, 1463-9		4
871	Next Generation Sequencing in Cancer Research, Volume 2. 2015 ,		4
870	Exploiting replicative stress to treat cancer. 2015 , 14, 405-23		188
869	Prospective derivation of a living organoid biobank of colorectal cancer patients. 2015 , 161, 933-45		1215
868	New trends in guided nanotherapies for digestive cancers: A systematic review. 2015 , 209, 288-307		68
867	Patient-derived bladder cancer xenografts: a systematic review. 2015 , 166, 324-31		25
866	Organoid development in cancer genome discovery. 2015 , 30, 42-8		40
865	Imaging tumor metabolism using positron emission tomography. 2015 , 21, 129-36		33
864	Local iontophoretic administration of cytotoxic therapies to solid tumors. 2015 , 7, 273ra14		44
863	An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. 2015 , 21, 3252-62		23
862	Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. 2015 , 32, 647-58		13
861	Preclinical mouse cancer models: a maze of opportunities and challenges. 2015 , 163, 39-53		363
860	Preclinical imaging and translational animal models of cancer for accelerated clinical implementation of nanotechnologies and macromolecular agents. 2015 , 219, 313-330		8
859	Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer. 2015 , 112, 12492-7		36

858	Failures in Phase III: Causes and Consequences. 2015 , 21, 4552-60	52
857	c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers. 2015 , 75, 4548-59	31
856	Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. 2015 , 133, 730-8	10
855	High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. 2015 , 21, 1318-25	752
854	Patient-Derived Xenografts as a Model System for Radiation Research. 2015 , 25, 273-80	29
853	Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. 2015 , 14, 119	35
852	The future of patient-derived tumor xenografts in cancer treatment. 2015 , 16, 1671-83	36
851	Targeting G-Quadruplex DNA Structures by EMICORON Has a Strong Antitumor Efficacy against Advanced Models of Human Colon Cancer. 2015 , 14, 2541-51	18
850	State of the art and future directions of pancreatic ductal adenocarcinoma therapy. 2015 , 155, 80-104	66
849	Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline. 2015 , 1, 877-894	54
848	Durability of Kinase-Directed Therapies--A Network Perspective on Response and Resistance. 2015 , 14, 1975-84	18
847	Label-free DNA imaging in vivo with stimulated Raman scattering microscopy. 2015 , 112, 11624-9	151
846	Preclinical Models Provide Scientific Justification and Translational Relevance for Moving Novel Therapeutics into Clinical Trials for Pediatric Cancer. 2015 , 75, 5176-5186	11
845	Patient-Derived Xenografts for Investigation of Acquired Resistance in Oncogene-Driven Cancers: Building a Better Mousetrap. 2015 , 33, 2839-40	16
844	An improved intrafemoral injection with minimized leakage as an orthotopic mouse model of osteosarcoma. 2015 , 486, 70-4	13
843	In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors. 2015 , 17, 473-80	13
842	Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic. 2015 , 1855, 61-82	43
841	Modelling bladder cancer in mice: opportunities and challenges. 2015 , 15, 42-54	85

840	Contemporary murine models in preclinical astrocytoma drug development. 2015 , 17, 12-28	19
839	Animal Models of Metastasis. 2015 , 95-123	
838	Genomic Instability and Cancer Metastasis. 2015 ,	1
837	Circulating tumour cells go green. 2015 , 64, 528-30	1
836	Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. 2015 , 30, 689-721	79
835	Receptor Tyrosine Kinases. 2015 ,	1
834	Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. 2015 , 14, 317-25	27
833	Mdm2 and aurora kinase a inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. 2015 , 75, 181-93	55
832	The role of surgeons in building a personalized medicine program. 2015 , 111, 3-8	3
831	Capillary Microsampling of Mouse Blood in Early Pre-Clinical Studies: A Preferred Alternative to Dried Blood Spot Sampling. 2016 , 08,	2
830	Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma. 2016 , 7, 5461-9	36
829	An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts. 2016 , 39, 77-86	86
828	Patient-derived xenograft models of colorectal cancer in pre-clinical research: a systematic review. 2016 , 7, 66212-66225	40
827	Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening. 2016 , 5,	143
826	Mouse Models in Prostate Cancer Translational Research: From Xenograft to PDX. 2016 , 2016, 9750795	37
825	Preclinical Cancer Models with the Potential to Predict Clinical Response. 2016 , 97-122	
824	Establishment of a tumour-stroma airway model (OncoCilAir) to accelerate the development of human therapies against lung cancer. 2016 , 44, 479-485	10
823	Patient-derived tumor xenograft strategies for informed management of patients with metastatic melanoma. 2016 , 26, 245-53	

822	Patient-derived xenografts as tools in pharmaceutical development. 2016 , 99, 612-21	35
821	Patient-derived xenografts: a relevant preclinical model for drug development. 2016 , 35, 189	76
820	Patient-Derived Xenograft: An Adjuvant Technology for the Treatment of Metastatic Disease. 2016 , 83, 170-6	19
819	Intracellular Doppler Signatures of Platinum Sensitivity Captured by Biodynamic Profiling in Ovarian Xenografts. 2016 , 6, 18821	9
818	Breast Cancer Stem Cells. 2016 , 133-151	
817	[Preclinical models in head and neck tumors : Evaluation of cellular and molecular resistance mechanisms in the tumor microenvironment]. 2016 , 64, 860-869	1
816	Modeling Breast Cancer Intertumor and Intratumor Heterogeneity Using Xenografts. 2016 , 81, 227-230	7
815	Anti-cancer effects of (Thunb.) Makino (). 2016 , 11, 43	28
814	PDX ou xBogrefe d'ivB de la tumeur du patient, la renaissance d'un modle oubli son implication dans la recherche et la clinique de demain. 2016 , 4, 237-245	0
813	Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways. 2016 , 8, 107	23
812	Ultra-sensitive diagnosis of orthotopic patient derived hepatocellular carcinoma by Fe@graphene nanoparticles in MRI. 2016 , 6, 113919-113923	19
811	In vivo photoacoustic tomography of EGFR overexpressed in hepatocellular carcinoma mouse xenograft. 2016 , 4, 43-54	9
810	Multiplexed Epitope-Based Tissue Imaging for Discovery and Healthcare Applications. 2016 , 2, 225-38	136
809	Advances in prostate cancer research models: From transgenic mice to tumor xenografting models. 2016 , 3, 64-74	6
808	Isolation of Pancreatic Cancer Cells from a Patient-Derived Xenograft Model Allows for Practical Expansion and Preserved Heterogeneity in Culture. 2016 , 186, 1537-46	23
807	Feedback Activation of Leukemia Inhibitory Factor Receptor Limits Response to Histone Deacetylase Inhibitors in Breast Cancer. 2016 , 30, 459-473	83
806	Computational models for predicting drug responses in cancer research. 2017 , 18, 820-829	79
805	Xenograft models for undifferentiated pleomorphic sarcoma not otherwise specified are essential for preclinical testing of therapeutic agents. 2016 , 12, 1257-1264	7

804	Colorectal Cancer Subtypes: Developmental Origin and Microenvironmental Regulation. 2016 , 2, 505-518	34
803	Preclinical models for interrogating drug action in human cancers using Stable Isotope Resolved Metabolomics (SIRM). 2016 , 12, 1	20
802	Clinical Outcomes of TP53 Mutations in Cancers. 2016 , 6,	35
801	Patient-derived tumor xenograft models for melanoma drug discovery. 2016 , 11, 895-906	14
800	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. 2016 , 167, 260-274.e22	274
799	Heralding a new paradigm in 3D tumor modeling. 2016 , 108, 197-213	98
798	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. 2016 , 127, 2203-13	51
797	Tumor deconstruction as a tool for advanced drug screening and repositioning. 2016 , 111, 815-819	2
796	Basal Tumor Cell Isolation and Patient-Derived Xenograft Engraftment Identify High-Risk Clinical Bladder Cancers. 2016 , 6, 35854	12
795	Isolation and characterization of tumorspheres from a recurrent pineoblastoma patient: Feasibility of a patient-derived xenograft. 2016 , 49, 569-78	10
794	One microenvironment does not fit all: heterogeneity beyond cancer cells. 2016 , 35, 601-629	41
793	The Role of Cancer Stem Cells in Tumour Radioresponse. 2016 , 43-74	
792	Comprehensive characterization of the patient-derived xenograft and the paralleled primary hepatocellular carcinoma cell line. 2016 , 16, 41	12
791	Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. 2016 , 6, 22172	69
790	Self-assembly of vascularized tissue to support tumor explants in vitro. 2016 , 8, 1301-1311	8
789	Culture on 3D Chitosan-Hyaluronic Acid Scaffolds Enhances Stem Cell Marker Expression and Drug Resistance in Human Glioblastoma Cancer Stem Cells. 2016 , 5, 3173-3181	44
788	Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. 2016 ,	10
787	Depletion of Mouse Cells from Human Tumor Xenografts Significantly Improves Downstream Analysis of Target Cells. 2016 ,	3

786	Labeling of Breast Cancer Patient-derived Xenografts with Traceable Reporters for Tumor Growth and Metastasis Studies. 2016,	12
785	Human lung adenocarcinoma cell cultures derived from malignant pleural effusions as model system to predict patients chemosensitivity. 2016, 14, 61	35
784	Molecular Pathology of Patient Tumors, Patient-Derived Xenografts, and Cancer Cell Lines. 2016, 76, 4619-26	27
783	Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. 2016, 375, 384-389	31
782	Assay Establishment and Validation of a High-Throughput Screening Platform for Three-Dimensional Patient-Derived Colon Cancer Organoid Cultures. 2016, 21, 931-41	84
781	Cancer Drug Development Using Drosophila as an in vivo Tool: From Bedside to Bench and Back. 2016, 37, 789-806	46
780	IGF-1 receptor targeted nanoparticles for image-guided therapy of stroma-rich and drug resistant human cancer. 2016, 9836,	3
779	In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer. 2016, 16, 133-147	77
778	Intramuscular Transplantation Improves Engraftment Rates for Esophageal Patient-Derived Tumor Xenografts. 2016, 23, 305-11	20
777	Pan-HER Inhibitor Augments Radiation Response in Human Lung and Head and Neck Cancer Models. 2016, 22, 633-43	16
776	Drug sensitivity testing platforms for gastric cancer diagnostics. 2016, 69, 93-6	1
775	Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in Patients of Early-Stage Large Cell Lung Cancer. 2016, 22, 2167-76	13
774	LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. 2016, 34, 49-60	21
773	Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies. 2016, 27, 1190-8	109
772	3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors. 2016, 15, 753-63	24
771	Cancer genomics: opportunities for medicinal chemistry?. 2016, 8, 357-9	3
770	Preclinical models of pancreatic ductal adenocarcinoma. 2016, 238, 197-204	71
769	Organoids derived from digestive tract, liver, and pancreas. 2016, 17, 3-10	10

768	Optimizing mouse models for precision cancer prevention. 2016 , 16, 187-96	48
767	Pharmacogenetics and pharmacogenomics as tools in cancer therapy. 2016 , 31, 25-34	18
766	Stimulated Raman scattering microscopy: an emerging tool for drug discovery. 2016 , 45, 2075-89	141
765	Antiangiogenic therapy in oncology: current status and future directions. 2016 , 388, 518-29	507
764	Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine. 2016 , 57 Suppl 1, 60S-8S	24
763	Organoids as Models for Neoplastic Transformation. 2016 , 11, 199-220	50
762	Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment. 2016 , 22, 1787-99	22
761	Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization. 2016 , 10, 104-10	15
760	Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. 2016 , 6, 286-99	172
759	Proteomic Characterization of Head and Neck Cancer Patient-Derived Xenografts. 2016 , 14, 278-86	41
758	Biomaterials and emerging anticancer therapeutics: engineering the microenvironment. 2016 , 16, 56-66	266
757	Mouse models of DNA mismatch repair in cancer research. 2016 , 38, 140-146	20
756	Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches. 2016 , 32, 127-137	53
755	An HRE-Binding Py-Im Polyamide Impairs Hypoxic Signaling in Tumors. 2016 , 15, 608-17	13
754	Xenograft models for adrenocortical carcinoma. 2016 , 421, 28-33	10
753	The bone marrow niche in support of breast cancer dormancy. 2016 , 380, 263-71	27
752	Studying cancer metastasis: Existing models, challenges and future perspectives. 2016 , 97, 107-17	26
751	XactMice: humanizing mouse bone marrow enables microenvironment reconstitution in a patient-derived xenograft model of head and neck cancer. 2016 , 35, 290-300	94

750	Animal models in translational medicine: Validation and prediction. 2017 , 2, 5	142
749	HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models. 2017 , 23, 677-686	46
748	c-Myc Alteration Determines the Therapeutic Response to FGFR Inhibitors. 2017 , 23, 974-984	21
747	Combine and conquer: challenges for targeted therapy combinations in early phase trials. <i>Nature Reviews Clinical Oncology</i> , 2017 , 14, 57-66	19.4 165
746	Establishment and characterization of a canine soft tissue sarcoma patient-derived xenograft model. 2017 , 15, 754-763	2
745	Interrogating open issues in cancer precision medicine with patient-derived xenografts. 2017 , 17, 254-268	369
744	Novel iodinated gold nanoclusters for precise diagnosis of thyroid cancer. 2017 , 9, 2219-2231	27
743	Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. 2017 , 65, 1948-1962	28
742	Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy. 2017 , 14, 940-952	40
741	Experimental animal modeling for immuno-oncology. 2017 , 173, 34-46	25
740	Generation of patient-derived xenografts from fine needle aspirates or core needle biopsy. 2017 , 161, 1246-1254	14
739	Conditional reprogramming and long-term expansion of normal and tumor cells from human biospecimens. 2017 , 12, 439-451	149
738	Patient-derived xenografts as in vivo models for research in urological malignancies. 2017 , 14, 267-283	49
737	Explant Cultures of Non-Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy. 2017 , 77, 2029-2039	50
736	Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. 2017 , 19, 9	64
735	DNA damage repair and survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy. 2017 , 140, 2587-2595	21
734	LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease and Serve as Models for Evaluating Cancer Therapeutics. 2017 , 77, 654-671	128
733	Functional Coupling of Human Microphysiology Systems: Intestine, Liver, Kidney Proximal Tubule, Blood-Brain Barrier and Skeletal Muscle. 2017 , 7, 42296	157

732	Successively activatable ultrasensitive probe for imaging tumour acidity and hypoxia. 2017 , 1,	119
731	Dehydroascorbic Acids-modified Polymer Micelles Target Cancer Cells to Enhance Anti-tumor Efficacy of Paclitaxel. 2017 , 7, 975	8
730	Hippo pathway mediates resistance to cytotoxic drugs. 2017 , 114, E3729-E3738	40
729	Antitumor Effect of AZD4547 in a Fibroblast Growth Factor Receptor 2-Amplified Gastric Cancer Patient-Derived Cell Model. 2017 , 10, 469-475	21
728	Use of precision methods to accelerate drug development in oncology. 2017 , 2, 109-120	
727	Modeling of Patient-Derived Xenografts in Colorectal Cancer. 2017 , 16, 1435-1442	23
726	Preclinical models for translational sarcoma research. 2017 , 29, 275-285	8
725	Gold nanoclusters-assisted delivery of NGF siRNA for effective treatment of pancreatic cancer. 2017 , 8, 15130	184
724	Next-Generation Sequencing Analysis and Algorithms for PDX and CDX Models. 2017 , 15, 1012-1016	28
723	Impact of MLH1 expression on tumor evolution after curative surgical tumor resection in a murine orthotopic xenograft model for human MSI colon cancer. 2017 , 56, 681-690	2
722	Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers. 2017 , 7, 1030-1045	23
721	Mechanisms of Molecular Carcinogenesis [Volume 2. 2017 ,	1
720	Drug delivery to melanoma brain metastases: Can current challenges lead to new opportunities?. 2017 , 123, 10-25	20
719	Metformin Inhibits Cellular Proliferation and Bioenergetics in Colorectal Cancer Patient-Derived Xenografts. 2017 , 16, 2035-2044	24
718	Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS. 2017 , 9,	94
717	Development of Novel Patient-Derived Preclinical Models from Malignant Effusions in Patients with Tyrosine Kinase Inhibitor-Resistant Clear Cell Renal Cell Carcinoma. 2017 , 10, 304-310	2
716	Beyond precision surgery: Molecularly motivated precision care for gastric cancer. 2017 , 43, 856-864	10
715	models in breast cancer research: progress, challenges and future directions. 2017 , 10, 359-371	86

714	Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. 2017 , 8, 14864	78
713	B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. 2017 , 23, 4212-4223	34
712	Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways. 2017 , 17, 191	17
711	Developments and future clinical outlook of taxane nanomedicines. 2017 , 253, 137-152	26
710	Modeling nasopharyngeal carcinoma in three dimensions. 2017 , 13, 2034-2044	15
709	Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. 2017 , 140, 1356-1363	18
708	Ex Vivo Engineering of the Tumor Microenvironment. 2017 ,	2
707	Introduction to Ex Vivo Cancer Models. 2017 , 1-12	1
706	Patient-Derived Xenografts in Oncology. 2017 , 13-40	
705	The Cancer Secretome. 2017 , 95-120	
704	The Importance of Circulating Tumor Cells and Tumor Models in Future of Cancer Therapy. 2017 , 121-135	
703	Preclinical mouse solid tumour models: status quo, challenges and perspectives. 2017 , 17, 751-765	151
702	PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models. 2017 , 77, e62-e66	65
701	Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. 2017 , 7, 12277	17
700	EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. 2017 , 77, 6651-6666	45
699	Patient-derived xenografts undergo mouse-specific tumor evolution. 2017 , 49, 1567-1575	384
698	Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. 2017 , 20, 81-91	6
697	mTOR co-targeting strategies for head and neck cancer therapy. 2017 , 36, 491-502	34

696	Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53. 2017 , 38, 908-927	28
695	Molecular Characteristics of Patient-Derived Tumor Xenografts: Similarities to Patient Tumors and Relevance for Biomarker Discovery. 2017 , 227-243	1
694	Fidelity and Stability of PDX Models. 2017 , 29-42	1
693	Humanized Mouse and Rat PDX Cancer Models. 2017 , 43-57	
692	Application of PDX Cancer Models in Co-clinical Trials and Personalized/Precision Medicine. 2017 , 177-192	1
691	The Use of Pediatric Patient-Derived Xenografts for Identifying Novel Agents and Combinations. 2017 , 133-159	2
690	The Tissue-Reconstructing Ability of Colon CSCs Is Enhanced by FK506 and Suppressed by GSK3 Inhibition. 2017 , 15, 1455-1466	6
689	Patient-Derived Xenografts as Cancer Models for Preclinical Drug Screening. 2017 , 141-154	1
688	Targeting ornithine decarboxylase (ODC) inhibits esophageal squamous cell carcinoma progression. 2017 , 1, 13	10
687	RNAi screen identifies essential regulators of human brain metastasis-initiating cells. 2017 , 134, 923-940	19
686	Engineering Advanced Models of the Glioblastoma Microenvironment Using Biomaterials. 2017 , 75-89	
685	Orientation of Preclinical Research in Ovarian Cancer. 2017 , 27, 1579-1586	
684	3D Cell Culture Models. 2017 , 251-275	
683	Patient-Derived Tumor Xenografts: Historical Background. 2017 , 1-9	
682	Extracellular Matrix in Tumor Biology. 2017 ,	1
681	When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. 2017 , 15, 354-361	2
680	Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. 2017 , 21, 1936-1952	45
679	Mouse Models of Breast Cancer: Deceptions that Reveal the Truth. 2017 , 49-60	

678	First-Generation Tumor Xenografts: A Link Between Patient-Derived Xenograft Models and Clinical Disease. 2017 , 155-176	1
677	Lessons Learned from Two Decades of Anticancer Drugs. 2017 , 38, 852-872	53
676	Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. 2017 , 7, 4712	29
675	Patient-Derived Xenograft Models of Human Cancer. 2017 ,	5
674	Current status and perspectives of patient-derived xenograft models in cancer research. 2017 , 10, 106	162
673	Facile Synthesis of ⁶⁴ Cu-Doped Au Nanocages for Positron Emission Tomography Imaging. 2017 , 3, 44-50	12
672	Metabolic Evaluation of Non-Small Cell Lung Cancer Patient-Derived Xenograft Models Using ¹⁸ F-FDG PET: A Potential Tool for Early Therapy Response. 2017 , 58, 42-47	6
671	Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. 2017 , 23, 1263-1273	67
670	Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts. 2017 , 140, 197-207	20
669	Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?. 2017 , 90, 20160441	32
668	AC220 and AraC cause differential inhibitory dynamics in patient-derived M5-AML with FLT3-ITD and, thus, ultimately distinct therapeutic outcomes. 2017 , 45, 36-44.e2	5
667	Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments. 2017 , 19, 44-50	11
666	Cancer Stem Cells in Squamous Cell Carcinoma. 2017 , 137, 31-37	19
665	The Dawning of Translational Breast Cancer: From Bench to Bedside. 2017 , 1026, 1-25	
664	Establishment and evaluation of four different types of patient-derived xenograft models. 2017 , 17, 122	10
663	Neural Biclustering in Gene Expression Analysis. 2017 ,	1
662	Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents. 2017 , 127, 3689-3701	53
661	Novel strategies to prevent the development of multidrug resistance (MDR) in cancer. 2017 , 8, 84559-84571	93

660	Integrins as Therapeutic Targets: Successes and Cancers. 2017 , 9,	131
659	Advances in Precision Medicine: Tailoring Individualized Therapies. 2017 , 9,	14
658	Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma. 2016 , 7, 690	114
657	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. 2017 , 8, 829	119
656	Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases. 2017 , 7, 252	23
655	Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. 2017 , 5,	49
654	In vivo and ex vivo cetuximab sensitivity assay using three-dimensional primary culture system to stratify KRAS mutant colorectal cancer. 2017 , 12, e0174151	17
653	Patient-derived xenograft in zebrafish embryos: a new platform for translational research in gastric cancer. 2017 , 36, 160	49
652	Management and potentialities of primary cancer cultures in preclinical and translational studies. 2017 , 15, 229	43
651	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. 2017 , 19, 130	36
650	Three-dimensional organotypic matrices from alternative collagen sources as pre-clinical models for cell biology. 2017 , 7, 16887	16
649	Patient-Derived Tumor Xenografts in Hematologic Disorders. 2017 , 305-339	1
648	Advances in Organoid Culturing of Patient-Derived Tumors. 2017 , 365-375	
647	PDX Models: History and Development. 2017 , 1-12	2
646	Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer. 2017 , 18,	3
645	Patient-Derived Xenografting of Human Melanoma. 2017 , 341-363	
644	The role of mouse models in translational cancer research: present and future directions. 2017 , 1,	1
643	Immunodeficient Mice: The Backbone of Patient-Derived Tumor Xenograft Models. 2017 , 57-73	4

642	Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model. 2018 , 25, 1637-1648	
641	Antitumor activity of kinetochore-associated protein 2 siRNA against lung cancer patient-derived tumor xenografts. 2018 , 15, 4676-4682	1
640	Pediatric brain tumors: Update of proteome-based studies. 2018 , 188, 41-45	3
639	Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type. 2018 , 98, 947-956	17
638	Nanomaterials for Cancer Precision Medicine. 2018 , 30, e1705660	92
637	Novel cancer gene variants and gene fusions of triple-negative breast cancers (TNBCs) reveal their molecular diversity conserved in the patient-derived xenograft (PDX) model. 2018 , 428, 127-138	9
636	Colon cancers carrying BRAF V600E and Ectatenin T41A activating mutations are resistant to numerous common anticancer drugs. 2018 , 15, 4471-4476	2
635	Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. 2018 , 6, 671-684	15
634	Mechanistic Exploration of Cancer Stem Cell Marker Voltage-Dependent Calcium Channel α_1 Subunit-mediated Chemotherapy Resistance in Small-Cell Lung Cancer. 2018 , 24, 2148-2158	29
633	Orthotopic Patient-Derived Glioblastoma Xenografts in Mice. 2018 , 1741, 183-190	13
632	A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. 2018 , 169, 381-390	12
631	Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine. 2018 , 1869, 117-127	68
630	Innovative methods for biomarker discovery in the evaluation and development of cancer precision therapies. 2018 , 37, 125-145	9
629	Human-cell-derived organoids as a new ex vivo model for drug assays in oncology. 2018 , 23, 857-863	17
628	Patient Derived Xenografts (PDX) for personalized treatment of pancreatic cancer: emerging allies in the war on a devastating cancer?. 2018 , 188, 107-118	13
627	Development of new preclinical models to advance adrenocortical carcinoma research. 2018 , 25, 437-451	27
626	Glioblastoma. 2018 ,	
625	Preclinical MRI. 2018 ,	2

624	Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib. 2018 , 135, 779-798	12
623	Dual Drug Backboned Shattering Polymeric Theranostic Nanomedicine for Synergistic Eradication of Patient-Derived Lung Cancer. 2018 , 30, 1706220	95
622	Magnetic Resonance Spectroscopy Studies of Mouse Models of Cancer. 2018 , 1718, 331-345	1
621	Personalized Cancer Medicine: An Organoid Approach. 2018 , 36, 358-371	116
620	Using gene expression data to direct breast cancer therapy: evidence from a preclinical trial. 2018 , 96, 111-117	6
619	Patient-derived xenograft models in musculoskeletal malignancies. 2018 , 16, 107	17
618	Targeting AKT with Oridonin Inhibits Growth of Esophageal Squamous Cell Carcinoma and Patient-Derived Xenografts. 2018 , 17, 1540-1553	43
617	Colorectal Cancer. 2018 ,	
616	Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. 2018 , 2, 239-253	12
615	Highlights from the Literature. 2018 , 20, 441-444	78
614	Patient-Derived Xenograft Models of Colorectal Cancer: Procedures for Engraftment and Propagation. 2018 , 1765, 307-314	4
613	Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. 2018 , 24, 2935-2943	15
612	Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer. 2018 , 170, 221-234	16
611	Are we ready to take full advantage of patient-derived tumor xenograft models?. 2018 , 36, 24-27	1
610	Developing a xenograft human tumor model in immunocompetent mice. 2018 , 412, 256-263	10
609	ALK Inhibitor Response in Melanomas Expressing Fusions and Alternate Isoforms. 2018 , 17, 222-231	24
608	Focus on Gynecologic Malignancies. 2018 ,	
607	Emerging tumor spheroids technologies for 3D in vitro cancer modeling. 2018 , 184, 201-211	90

606	Cerenkov luminescence imaging on evaluation of early response to chemotherapy of drug-resistant gastric cancer. 2018 , 14, 205-213	18
605	Urothelial Carcinoma. 2018 ,	
604	Xenograft as In Vivo Experimental Model. 2018 , 1692, 97-105	3
603	Biomechanical regulation of drug sensitivity in an engineered model of human tumor. 2018 , 150, 150-161	38
602	Patient-derived xenografts as preclinical neuroblastoma models. 2018 , 372, 233-243	30
601	Patient-Derived Bladder Cancer Xenografts. 2018 , 1655, 169-175	2
600	The promise of signal transduction in genetically driven sarcomas of the nerve. 2018 , 299, 317-325	11
599	Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases. 2018 , 37, 1237-1250	33
598	Etk Interaction with PFKFB4 Modulates Chemoresistance of Small-cell Lung Cancer by Regulating Autophagy. 2018 , 24, 950-962	34
597	Animal Models of Melanoma. 2018 , 1-31	1
596	Comparison of Clinical Features and Outcomes in Epithelial Ovarian Cancer according to Tumorigenicity in Patient-Derived Xenograft Models. 2018 , 50, 956-963	15
595	Establishment of Patient-Derived Tumor Xenograft Models of High-Risk Endometrial Cancer. 2018 , 28, 1812-1820	6
594	The Generation and Application of Patient-Derived Xenograft Model for Cancer Research. 2018 , 50, 1-10	135
593	Challenges in Stratifying the Molecular Variability of Patient-Derived Colon Tumor Xenografts. 2018 , 2018, 2954208	11
592	Experimental Animal Models of HIV/AIDS for Vaccine Trials. 2018 ,	
591	Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity. 2018 , 87, 49-57	59
590	Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research. 2018 , 59, 247-262	31
589	Chemoresistance of Cancer Cells: Requirements of Tumor Microenvironment-mimicking Models in Anti-Cancer Drug Development. 2018 , 8, 5259-5275	89

588	Comparison between NOD/SCID mice and BALB/c mice for patient-derived tumor xenografts model of non-small-cell lung cancer. 2018 , 10, 6695-6703	4
587	Using Mouse and Models to Investigate the Mechanistic Links between Diet, Obesity, Type II Diabetes, and Cancer. 2018 , 19,	12
586	Generation of patient-derived tumor xenografts from percutaneous tumor biopsies in children with bone sarcomas. 2019 , 66, e27579	9
585	Three-Dimensional Organoids in Cancer Research: The Search for the Holy Grail of Preclinical Cancer Modeling. 2018 , 22, 733-748	22
584	Emerging Technologies for Cancer Research: Towards Personalized Medicine with Microfluidic Platforms and 3D Tumor Models. 2018 , 25, 4616-4637	16
583	Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. 2018 , 5, 42-49	3
582	PLK1 as a potential prognostic marker of gastric cancer through MEK-ERK pathway on PDX models. 2018 , 11, 6239-6247	9
581	A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. 2018 , 17, 2702-2709	19
580	Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma. 2018 , 37, 233	15
579	Self-Supplied Tumor Oxygenation through Separated Liposomal Delivery of HO and Catalase for Enhanced Radio-Immunotherapy of Cancer. 2018 , 18, 6360-6368	158
578	PATIENT-DERIVED XENOGRAFTS AS A PRECLINICAL MODEL FOR BONE SARCOMAS. 2018 , 26, 98-102	8
577	Modeling Hematological Diseases and Cancer With Patient-Specific Induced Pluripotent Stem Cells. 2018 , 9, 2243	3
576	Implantable pre-metastatic niches for the study of the microenvironmental regulation of disseminated human tumour cells. 2018 , 2, 915-929	41
575	Chromatin run-on and sequencing maps the transcriptional regulatory landscape of glioblastoma multiforme. 2018 , 50, 1553-1564	56
574	Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response. 2018 , 11,	2
573	Recent advances in combinatorial drug screening and synergy scoring. 2018 , 42, 102-110	49
572	Methodology, Criteria, and Characterization of Patient-Matched Thyroid Cell Lines and Patient-Derived Tumor Xenografts. 2018 , 103, 3169-3182	6
571	Renal cancer: new models and approach for personalizing therapy. 2018 , 37, 217	9

570	Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy. 2018 , 10, 1301-1311	37
569	Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors. 2018 , 175, 186-199.e19	94
568	Genetics and biology of prostate cancer. 2018 , 32, 1105-1140	199
567	Computational approach to discriminate human and mouse sequences in patient-derived tumour xenografts. 2018 , 19, 19	35
566	Translational models of prostate cancer bone metastasis. 2018 , 15, 403-421	52
565	Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. 2018 , 9, 1978	119
564	Galangin potential as a functional food ingredient. 2018 , 46, 490-503	21
563	Combinatorial Drug Testing in 3D Microtumors Derived from GBM Patient-Derived Xenografts Reveals Cytotoxic Synergy in Pharmacokinomics-informed Pathway Interactions. 2018 , 8, 8412	8
562	Soluble stroma-related biomarkers of pancreatic cancer. 2018 , 10,	30
561	Early-drug development in the era of immuno-oncology: are we ready to face the challenges?. 2018 , 29, 1727-1740	12
560	Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues. 2018 , 40, 635-646	18
559	Poly lactide-tethered prodrugs in polymeric nanoparticles as reliable nanomedicines for the efficient eradication of patient-derived hepatocellular carcinoma. 2018 , 8, 3949-3963	45
558	A comparison of next-generation sequencing analysis methods for cancer xenograft samples. 2018 , 45, 345-350	2
557	Genome sequencing in the clinic: the past, present, and future of genomic medicine. 2018 , 50, 563-579	31
556	Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. 2018 , 8, 4	113
555	Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. 2018 , 8, 23	53
554	Personalized Medicine in Malignant Melanoma: Towards Patient Tailored Treatment. 2018 , 8, 202	26
553	Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy. 2018 , 19,	20

552	Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients. 2018 , 38, 48	18
551	Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. 2018 , 2, 14	15
550	Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. 2018 , 17, 2112-2122	19
549	Improving zebrafish embryo xenotransplantation conditions by increasing incubation temperature and establishing a proliferation index with ZFtool. 2018 , 18, 3	28
548	A PDX/Organoid Biobank of Advanced Prostate Cancers Captures Genomic and Phenotypic Heterogeneity for Disease Modeling and Therapeutic Screening. 2018 , 24, 4332-4345	100
547	PDXliver: a database of liver cancer patient derived xenograft mouse models. 2018 , 18, 550	13
546	Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance. 2018 , 38, 19	10
545	Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. 2018 , 13, e0195932	5
544	Systematic Review: Characteristics and Preclinical Uses of Bladder Cancer Cell Lines. 2018 , 4, 169-183	29
543	Advantages of patient-derived orthotopic mouse models and genetic reporters for developing fluorescence-guided surgery. 2018 , 118, 253-264	16
542	gpGrouper: A Peptide Grouping Algorithm for Gene-Centric Inference and Quantitation of Bottom-Up Proteomics Data. 2018 , 17, 2270-2283	27
541	Patient-Derived Xenograft Models for Endometrial Cancer Research. 2018 , 19,	18
540	Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. 2018 , 124, 168-178	15
539	Modeling Endometrial Cancer: Past, Present, and Future. 2018 , 19,	49
538	Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo. 2018 , 123, 546-559	18
537	In vitro and in vivo characterization of pharmaceutical topical nanocarriers containing anticancer drugs for skin cancer treatment. 2018 , 563-627	5
536	A novel immunodeficient rat model supports human lung cancer xenografts. 2019 , 33, 140-150	14
535	Quantifying and Processing Biomedical and Behavioral Signals. 2019 ,	1

534 Animal Models of Melanoma. **2019**, 303-333

533 Spontaneous evolution of human skin fibroblasts into wound-healing keratinocyte-like cells. **2019**, 9, 5200-5213

5

532 Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models. **2019**, 8,

80

531 Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. **2019**, 203, 107395

35

530 Pregnancy and Breast Cancer: Pathways to Understand Risk and Prevention. **2019**, 25, 866-881

29

529 Animal models of well-differentiated/dedifferentiated liposarcoma: utility and limitations. **2019**, 12, 5257-5268

2

528 Semalytics: a semantic analytics platform for the exploration of distributed and heterogeneous cancer data in translational research. **2019**, 2019,

1

527 Models used to screen for the treatment of multidrug resistant cancer facilitated by transporter-based efflux. **2019**, 145, 1949-1976

3

526 Fidelity of a PDX-CR model for bladder cancer. **2019**, 517, 49-56

12

525 The Melding of Drug Screening Platforms for Melanoma. **2019**, 9, 512

15

524 Hepatocellular Carcinoma Xenografts Established From Needle Biopsies Preserve the Characteristics of the Originating Tumors. **2019**, 3, 971-986

15

523 Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization. **2019**, 8,

7

522 Expression and Role of MicroRNAs from the miR-200 Family in the Tumor Formation and Metastatic Propensity of Pancreatic Cancer. **2019**, 17, 491-503

25

521 A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer. **2019**, 8, 5148-5157

29

520 Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines. **2019**, 12, 92

14

519 Contemporary preclinical human models of adrenocortical carcinoma. **2019**, 8, 139-144

3

518 Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. **2019**, 79, 5612-5625

8

517 Patient-derived organoids (PDOs) as a novel in vitro model for neuroblastoma tumours. **2019**, 19, 970

15

516	An interventional image-guided microdevice implantation and retrieval method for in-vivo drug response assessment. 2019 , 46, 5134-5143	3
515	Development of a MEL Cell-Derived Allograft Mouse Model for Cancer Research. 2019 , 11,	1
514	Androgen Receptor Is a Non-canonical Inhibitor of Wild-Type and Mutant Estrogen Receptors in Hormone Receptor-Positive Breast Cancers. 2019 , 21, 341-358	15
513	A multi-modal data resource for investigating topographic heterogeneity in patient-derived xenograft tumors. 2019 , 6, 253	4
512	Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify -Mutant Lung Cancers. 2019 , 18, 1863-1874	3
511	Magnetic Resonance Imaging for Translational Research in Oncology. 2019 , 8,	4
510	Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks. 2019 , 8,	29
509	Targeted Drug-Loaded Chemical Probe Staining Assay to Predict Therapy Response and Function as an Independent Pathological Marker. 2019 , 21, 549-561	0
508	Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets. 2019 , 26, 77	13
507	Right Cu S@MnS Core-Shell Nanoparticles as a Photo/HO-Responsive Platform for Effective Cancer Theranostics. 2019 , 6, 1901461	30
506	Addressing Patient Specificity in the Engineering of Tumor Models. 2019 , 7, 217	30
505	Excipient-free nanodispersion of 7-ethyl-10-hydroxycamptothecin exerts potent therapeutic effects against pancreatic cancer cell lines and patient-derived xenografts. 2019 , 465, 36-44	3
504	Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. 2019 , 10, 3991	199
503	Current and Future Horizons of Patient-Derived Xenograft Models in Colorectal Cancer Translational Research. 2019 , 11,	20
502	Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Samples. 2019 , 9, 875	21
501	The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors. 2019 , 12,	65
500	Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts. 2019 , 58, 1489-1494	13
499	Distinct Transcriptional Programming Drive Response to MAPK Inhibition in -Mutant Melanoma Patient-Derived Xenografts. 2019 , 18, 2421-2432	1

498	Urine. 2019 ,	5
497	Animal models for modeling pancreatic cancer and novel drug discovery. 2019 , 14, 127-142	9
496	Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers. 2019 , 25, 2821-2834	8
495	The Application of Pre-clinical Animal Models to Optimise Nanoparticulate Drug Delivery for Hepatocellular Carcinoma. 2018 , 6, 221-231	2
494	Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors. 2019 , 26, 1518-1532.e9	36
493	The role of mouse tumour models in the discovery and development of anticancer drugs. 2019 , 121, 101-108	56
492	Patient-Derived Xenograft Models of Breast Cancer and Their Application. 2019 , 8,	53
491	Establishment of a non-small-cell lung cancer-liver metastasis patient-derived tumor xenograft model for the evaluation of patient-tailored chemotherapy. 2019 , 39,	1
490	Increased Cholesterol Biosynthesis Is a Key Characteristic of Breast Cancer Stem Cells Influencing Patient Outcome. 2019 , 27, 3927-3938.e6	62
489	Cancer modeling meets human organoid technology. 2019 , 364, 952-955	319
488	Patient-Derived Cancer Organoid Cultures to Predict Sensitivity to Chemotherapy and Radiation. 2019 , 25, 5376-5387	73
487	Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer. 2019 , 10, 413	15
486	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. 2019 , 96, 555-567	25
485	Improved Oxygen Supply to Multicellular Spheroids Using A Gas-permeable Plate and Embedded Hydrogel Beads. 2019 , 8,	5
484	AKR1C1 controls cisplatin-resistance in head and neck squamous cell carcinoma through cross-talk with the STAT1/3 signaling pathway. 2019 , 38, 245	26
483	A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model. 2019 , 116, 108987	11
482	Assessing drug response in engineered brain microenvironments. 2019 , 150, 21-34	5
481	Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors. 2019 , 8,	45

480	Mouse models of gastrointestinal cancers in drug development and research. 2019 , 267-292	
479	Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system. 2019 , 14, e0215080	2
478	Preclinical models in ovarian cancer. 2019 , 31-57	
477	Changes in the Urinary Proteome in a Patient-Derived Xenograft (PDX) Nude Mouse Model of Colorectal Tumor. 2019 , 9, 4975	6
476	Modeling Patient-Derived Glioblastoma with Cerebral Organoids. 2019 , 26, 3203-3211.e5	187
475	Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. 2019 , 19, 205	11
474	Target Identification and Validation in Drug Discovery. 2019 ,	
473	In Vivo Pharmacology Models for Cancer Target Research. 2019 , 1953, 183-211	3
472	Preclinical Organotypic Models for the Assessment of Novel Cancer Therapeutics and Treatment. 2019 , 225	1
471	Tumor organoids: From inception to future in cancer research. 2019 , 454, 120-133	23
470	Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. 2019 , 12, 38	38
469	Mouse-Derived Isograft (MDI) In Vivo Tumor Models I. Spontaneous sMDI Models: Characterization and Cancer Therapeutic Approaches. 2019 , 11,	2
468	Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. 2019 , 17, 1036-1048	5
467	DRAP: a toolbox for drug response analysis and visualization tailored for preclinical drug testing on patient-derived xenograft models. 2019 , 17, 39	4
466	MiR-223-3p functions as a tumor suppressor in lung squamous cell carcinoma by miR-223-3p-mutant p53 regulatory feedback loop. 2019 , 38, 74	24
465	mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy. 2019 , 20,	219
464	Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens. 2019 , 23, 818-824	13
463	Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. 2019 , 7, 37	77

462	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. 2019 , 35, 221-237.e8	157
461	The next generation personalized models to screen hidden layers of breast cancer tumorigenicity. 2019 , 175, 277-286	0
460	ISL1 predicts poor outcomes for patients with gastric cancer and drives tumor progression through binding to the ZEB1 promoter together with SETD7. 2019 , 10, 33	18
459	Clinical Implementation of Precision Medicine in Gastric Cancer. 2019 , 19, 235-253	6
458	An improved method to build lung cancer PDX models by surgical resection samples and its association with B7-H3 expression.. 2019 , 8, 2848-2857	
457	Development of colloidal rare-earth arsenites as arsenic trioxide nanoparticle prodrugs (ATONP) for chemotherapy on a patient-derived xenograft model of colorectal cancer. 2019 , 43, 17408-17415	
456	Murine xenograft bioreactors for human immunopeptidome discovery. 2019 , 9, 18558	6
455	Longitudinal micro-endoscopic monitoring of high-success intramucosal xenografts for mouse models of colorectal cancer. 2019 , 16, 1453-1460	4
454	A spontaneously metastatic model of bladder cancer: imaging characterization. 2019 , 17, 425	5
453	Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models. 2019 , 14, e0225082	6
452	Xenografts Derived From Patients' Ascites Recapitulate the Gemcitabine Resistance Observed in Pancreatic Cancer Patients. 2019 , 48, 1294-1302	2
451	Supervised Gene Identification in Colorectal Cancer. 2019 , 243-251	
450	DT-13 inhibited the proliferation of colorectal cancer via glycolytic metabolism and AMPK/mTOR signaling pathway. 2019 , 54, 120-131	16
449	3D in vitro models of tumors expressing EGFR family receptors: a potent tool for studying receptor biology and targeted drug development. 2019 , 24, 99-111	8
448	Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models. 2019 , 442, 82-90	32
447	On the contribution of mass spectrometry-based platforms to the field of personalized oncology. 2019 , 110, 129-142	3
446	Establishment of a Novel PDX Mouse Model and Evaluation of the Tumor Suppression Efficacy of Bortezomib Against Liposarcoma. 2019 , 12, 269-281	9
445	Circulating Tumor Cell-Derived Pre-Clinical Models for Personalized Medicine. 2018 , 11,	33

444	Nitroimidazole derivative incorporated liposomes for hypoxia-triggered drug delivery and enhanced therapeutic efficacy in patient-derived tumor xenografts. 2019 , 83, 334-348	47
443	E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity. 2019 , 18, e74-e86	15
442	Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient-derived tumor xenograft model. 2019 , 41, 1260-1269	3
441	A framework for the development of effective anti-metastatic agents. <i>Nature Reviews Clinical Oncology</i> , 2019 , 16, 185-204	19.4 119
440	Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. 2019 , 18, 278-288	14
439	Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification. 2019 , 144, 2782-2794	12
438	BRAF fusions identified in melanomas have variable treatment responses and phenotypes. 2019 , 38, 1296-1308	18
437	Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftment. 2019 , 12, 69-75	8
436	Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. 2020 , 146, 1606-1617	17
435	The GH-EXIN neural network for hierarchical clustering. 2020 , 121, 57-73	13
434	Patient-derived xenograft models-the future of personalised cancer treatment. 2020 , 122, 601-602	22
433	Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. 2020 , 122, 680-691	20
432	Inhibiting Translation Elongation with SVC112 Suppresses Cancer Stem Cells and Inhibits Growth in Head and Neck Squamous Carcinoma. 2020 , 80, 1183-1198	7
431	Patient-derived explants (PDEs) as a powerful preclinical platform for anti-cancer drug and biomarker discovery. 2020 , 122, 735-744	63
430	Patient-derived scaffolds uncover breast cancer promoting properties of the microenvironment. 2020 , 235, 119705	25
429	Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review. 2020 , 319, 135-156	85
428	Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma. 2020 , 12, 3327-3340	23
427	Recent Advances in Particulate Adjuvants for Cancer Vaccination. 2020 , 3, 1900115	7

426	An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance. 2020 , 19, 348-363	13
425	Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer. 2020 , 26, 17-26.e6	180
424	High-Dimensional Precision Medicine From Patient-Derived Xenografts. 2021 , 116, 1140-1154	2
423	Evaluation of the treatment strategies on patient-derived xenograft mice of human breast tumor. 2020 , 889, 173605	2
422	Culture and application of conditionally reprogrammed primary tumor cells. 2020 , 8, 224-233	0
421	Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model. 2020 , 15, e0236101	1
420	Patient-derived cell line, xenograft and organoid models in lung cancer therapy. 2020 , 9, 2214-2232	17
419	Patient-Derived Tumor Xenograft Models: Toward the Establishment of Precision Cancer Medicine. 2020 , 10,	18
418	Microenvironmental modulation of the developing tumour: an immune-stromal dialogue. 2021 , 15, 2600-2633	2
417	Rapid Microfluidic Formation of Uniform Patient-Derived Breast Tumor Spheroids.. 2020 , 3, 6273-6283	12
416	Characterization and comparison of genomic profiles between primary cancer cell lines and parent atypical meningioma tumors. 2020 , 20, 345	0
415	PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma. 2020 , 12,	7
414	Current Status and Perspectives of Patient-Derived Models for Ewing's Sarcoma. 2020 , 12,	3
413	Spontaneous and Induced Animal Models for Cancer Research. 2020 , 10,	14
412	Castacin Inhibits Growth of Xenograft Tumors of Human Oral Cancer SCC-4 Cells. 2020 , 34, 2461-2467	1
411	Molecular Targeted Radiosensitizers. 2020 ,	
410	Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. 2020 , 59, 1227-1240	4
409	A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. 2020 , 19, 2516-2527	6

408	Patient-Derived Urothelial Cancer Xenograft Models: A Systematic Review and Future Perspectives. 2020 , 6, 131-141	
407	A Primer on Human Brain Organoids for the Neurosurgeon. 2020 , 87, 620-629	5
406	Inhibition of PI3K by copanlisib exerts potent antitumor effects on Merkel cell carcinoma cell lines and mouse xenografts. 2020 , 10, 8867	4
405	Identification of Tumor Antigens in the HLA Peptidome of Patient-derived Xenograft Tumors in Mouse. 2020 , 19, 1360-1374	4
404	Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models. 2020 , 12,	17
403	First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. 2020 , 19, 1598-1612	9
402	An Animal Model of Colorectal Cancer Liver Metastasis With a High Metastasis Rate and Clonal Dynamics. 2020 , 40, 3297-3306	2
401	Current status and perspectives of patient-derived rare cancer models. 2020 , 33, 919-929	4
400	Xanthohumol Inhibits the Growth of Keratin 18-Overexpressed Esophageal Squamous Cell Carcinoma and. 2020 , 8, 366	5
399	In vivo PET/MRI Imaging of the Chorioallantoic Membrane. 2020 , 8,	3
398	Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents. 2020 , 117, 7021-7029	20
397	Biliary tract cancer patient-derived xenografts: Surgeon impact on individualized medicine. 2020 , 2, 100068	10
396	A Model of a Zebrafish Avatar for Co-Clinical Trials. 2020 , 12,	24
395	Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line. 2020 , 21, 495-502	2
394	Systematic Establishment of Robustness and Standards in Patient-Derived Xenograft Experiments and Analysis. 2020 , 80, 2286-2297	17
393	From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision Medicine. 2020 , 10, 117	9
392	Patient-Derived Xenograft Models in Urological Malignancies: Urothelial Cell Carcinoma and Renal Cell Carcinoma. 2020 , 12,	4
391	A clinically and genomically annotated nerve sheath tumor biospecimen repository. 2020 , 7, 184	6

390	An immune competent orthotopic model of endometrial cancer with metastasis. 2020 , 6, e04075	4
389	A fast, simple, and cost-effective method of expanding patient-derived xenograft mouse models of pancreatic ductal adenocarcinoma. 2020 , 18, 255	3
388	Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer. 2020 , 20, 592	4
387	Cotargeting CHK1 and PI3K Synergistically Suppresses Tumor Growth of Oral Cavity Squamous Cell Carcinoma in Patient-Derived Xenografts. 2020 , 12,	7
386	Tissue-guided LASSO for prediction of clinical drug response using preclinical samples. 2020 , 16, e1007607	11
385	TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer. 2020 , 11, 92	24
384	Novel Breast Cancer Brain Metastasis Patient-Derived Orthotopic Xenograft Model for Preclinical Studies. 2020 , 12,	12
383	Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma. 2020 , 26, 249-271	9
382	Bioinformatics and computational approaches for analyzing patient-derived disease models in cancer research. 2020 , 18, 375-380	3
381	Choosing The Right Animal Model for Renal Cancer Research. 2020 , 13, 100745	19
380	Three-dimensional in vitro cell culture devices using patient-derived cells for high-throughput screening of drug combinations. 2020 , 3, e10067	2
379	Orthotopic Implantation Achieves Better Engraftment and Faster Growth Than Subcutaneous Implantation in Breast Cancer Patient-Derived Xenografts. 2020 , 25, 27-36	7
378	Organoid of ovarian cancer: genomic analysis and drug screening. 2020 , 22, 1240-1251	16
377	Mouse models of high-risk neuroblastoma. 2020 , 39, 261-274	9
376	Acetylshikonin suppressed growth of colorectal tumour tissue and cells by inhibiting the intracellular kinase, T-lymphokine-activated killer cell-originated protein kinase. 2020 , 177, 2303-2319	11
375	Applications of patient-derived tumor xenograft models and tumor organoids. 2020 , 13, 4	99
374	Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis. 2020 , 174, 113795	31
373	Patient-Derived Orthotopic Xenograft Models of Pediatric Brain Tumors: In a Mature Phase or Still in Its Infancy?. 2019 , 9, 1418	6

372	Effects of anti-PD-1 immunotherapy on tumor regression: insights from a patient-derived xenograft model. 2020 , 10, 7078	5
371	The humanized mouse: Emerging translational potential. 2020 , 59, 830-838	8
370	CEREBRAL ORGANOID AS A MODEL FOR GLIOBLASTOMA MULTIFORME. 2020 , 13, 152-159	5
369	Zebrafish patient avatars in cancer biology and precision cancer therapy. 2020 , 20, 263-273	73
368	Enzyme-Triggered Transcytosis of Dendrimer-Drug Conjugate for Deep Penetration into Pancreatic Tumors. 2020 , 14, 4890-4904	53
367	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. 2020 , 26, 3720-3731	10
366	Establishment and characterization of patient-derived xenografts as preclinical models for head and neck cancer. 2020 , 20, 316	7
365	A Preliminary Study on the Establishment of the PDX Model. 2020 , 12, 1969-1979	0
364	MiniPDX-guided postoperative anticancer treatment can effectively prolong the survival of patients with hepatocellular carcinoma. 2021 , 87, 125-134	4
363	Organoid model: A new hope for pancreatic cancer treatment?. 2021 , 1875, 188466	9
362	New technologies in developing recombinant-attenuated bacteria for cancer therapy. 2021 , 118, 513-530	5
361	Electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer. 2021 , 266, 120432	19
360	MRI-guided focused ultrasound enhances drug delivery in experimental diffuse intrinsic pontine glioma. 2021 , 330, 1034-1045	10
359	The Essential Factors of Establishing Patient-derived Tumor Model. 2021 , 12, 28-37	7
358	Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies. 2021 , 157, 103190	0
357	The epidermal growth factor receptor variant type III mutation frequently found in gliomas induces astrogenesis in human cerebral organoids. 2021 , 54, e12965	7
356	Patient-Derived Prostate Cancer Explants: A Clinically Relevant Model to Assess siRNA-Based Nanomedicines. 2021 , 10, e2001594	5
355	In vitro bone metastasis dwelling in a 3D bioengineered niche. 2021 , 269, 120624	3

354	Novel aptasensor-based assay of sonic hedgehog ligand for detection of portal vein invasion of hepatocellular carcinoma. 2021 , 174, 112738	4
353	Current methods in translational cancer research. 2021 , 40, 7-30	7
352	An overview of machine learning methods for monotherapy drug response prediction. 2021 ,	1
351	Molecular phenotypes reveal heterogeneous engraftments of patient-derived hepatocellular carcinoma xenografts. 2021 , 33, 470-479	2
350	Establishment and Long-Term Expansion of Small Cell Lung Cancer Patient-Derived Tumor Organoids. 2021 , 22,	6
349	Models of ovarian cancer to test new agents. 2021 , 97-127	
348	Patient-Derived Xenografts from Solid Tumors (PDX) for Models of Metastasis. 2021 , 2294, 43-58	
347	Evolution of Experimental Models in the Study of Glioblastoma: Toward Finding Efficient Treatments. 2020 , 10, 614295	13
346	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. 2021 , 53, 86-99	44
345	In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles. 2021 , 1295, 271-299	2
344	SPA: A Quantitation Strategy for MS Data in Patient-derived Xenograft Models. 2021 ,	0
343	Xenograft models for pediatric cancer therapies. 2021 , 10, 11	1
342	Advanced Approaches to Breast Cancer Classification and Diagnosis. 2020 , 11, 632079	15
341	Benefits of Zebrafish Xenograft Models in Cancer Research. 2021 , 9, 616551	7
340	Design and Implementation of the Pre-Clinical DICOM Standard in Multi-Cohort Murine Studies. 2021 , 7, 1-9	0
339	Mechanisms of Cisplatin in Combination with Repurposed Drugs against Human Endometrial Carcinoma Cells. 2021 , 11,	2
338	Overcoming biological barriers to improve solid tumor immunotherapy. 2021 , 11, 2276-2301	4
337	Current status and future outlook for patient-derived cancer models from a rare cancer research perspective. 2021 , 112, 953-961	6

336	Patient-Derived Organoids as a Model for Cancer Drug Discovery. 2021 , 22,	7
335	Cancer models in preclinical research: A chronicle review of advancement in effective cancer research. 2021 , 4, 87-103	8
334	ProteaseGuru: A Tool for Protease Selection in Bottom-Up Proteomics. 2021 , 20, 1936-1942	6
333	Construction of patient-derived tumor models to evaluate anticancer agents and cancer immunotherapy. 2021 , 21, 406	3
332	The Role of Network Science in Glioblastoma. 2021 , 13,	2
331	Using the Microwell-mesh to culture microtissues in vitro and as a carrier to implant microtissues in vivo into mice. 2021 , 11, 5118	1
330	Three-Dimensional Macroporous Sponge for the Culture of Hepatocellular Carcinoma Patient-Derived Xenograft Organoids. 2021 , 26, 249-254	1
329	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. 2021 , 124, 1581-1591	4
328	Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma. 2021 , 21, 265	1
327	Applications of the Chick Chorioallantoic Membrane as an Alternative Model for Cancer Studies. 2021 , 1-16	11
326	Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels.	
325	Organoids Models for the Study of Cell-Cell Interactions.	1
324	Establishment of Nude Mice Lacking NK Cells and Their Application for Human Tumor Xenografts. 2021 , 22, 1069-1074	1
323	A multicenter clinical study: personalized medication for advanced gastrointestinal carcinomas with the guidance of patient-derived tumor xenograft (PDTX). 2021 , 1	1
322	Mimicking and surpassing the xenograft model with cancer-on-chip technology. 2021 , 66, 103303	1
321	Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance. 2021 , 8, 12	18
320	Enhanced tumour penetration and prolonged circulation in blood of polyzwitterion-drug conjugates with cell-membrane affinity. 2021 , 5, 1019-1037	37
319	Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas. 2021 , 7, 338-349	2

318	Establishing an immunocompromised porcine model of human cancer for novel therapy development with pancreatic adenocarcinoma and irreversible electroporation. 2021 , 11, 7584	4
317	Statistical analysis of comparative tumor growth repeated measures experiments in the ovarian cancer patient derived xenograft (PDX) setting. 2021 , 11, 8076	2
316	Molecular Biology of Pediatric and Adult Male Germ Cell Tumors. 2021 , 13,	3
315	Establishment and characterization of an ovarian yolk sac tumor patient-derived xenograft model. 2021 , 37, 1031-1040	0
314	Targeting LIMK1 with luteolin inhibits the growth of lung cancer in vitro and in vivo. 2021 , 25, 5560-5571	10
313	Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. 2021 , 21, 262	9
312	A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy. 2021 , 11, 692403	1
311	Patient-derived tumor models: a more suitable tool for pre-clinical studies in colorectal cancer. 2021 , 40, 178	10
310	Application and research progress of in vitro liver cancer cell culture models. 2021 , 29, 563-570	0
309	Increased Tumor Growth Rate and Mesenchymal Properties of NSCLC-Patient-Derived Xenograft Models during Serial Transplantation. 2021 , 13,	2
308	Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives. 2021 , 11, 682872	5
307	Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets. 2021 , 12, 3946	5
306	Patient-derived xenograft models for the study of benign human neoplasms. 2021 , 120, 104630	2
305	Inhibition of nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the nicotinamide adenine dinucleotide salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress. 2021 ,	3
304	PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. 2021 , 12, 4626	4
303	Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. 2021 , 11, 704042	0
302	Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck Cancer. 2021 , 9, 666515	2
301	Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models. 2021 , 174, 265-293	13

300	Impact of photobiomodulation in a patient-derived xenograft model of oral squamous cell carcinoma. 2021,	1
299	Establishment and preclinical application of a patient-derived xenograft model for uterine cancer. 2021, 162, 173-181	2
298	Zebrafish Patient-Derived Xenografts Identify Chemo-Response in Pancreatic Ductal Adenocarcinoma Patients. 2021, 13,	4
297	Model Selection for the Preclinical Development of New Drug-Radiotherapy Combinations. 2021, 33, 694-704	1
296	Dendrimeric nanosystem consistently circumvents heterogeneous drug response and resistance in pancreatic cancer. 2021, 1, 21-34	23
295	Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. 2021, 2, 100373	1
294	Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic. 2021, 111, e38-e53	2
293	Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. 2021, 20, 2049-2060	2
292	Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. 2021, 12, 5086	6
291	Two Antibody-Guided Lactic-co-Glycolic Acid-Polyethylenimine (LGA-PEI) Nanoparticle Delivery Systems for Therapeutic Nucleic Acids. 2021, 14,	3
290	Establishment and Characterization of Feline Mammary Tumor Patient-Derived Xenograft Model. 2021, 11,	1
289	Carcinosarcoma of the stomach with alpha-fetoprotein-producing hepatoid adenocarcinoma: an unexpected combination of two rare subtypes of gastric cancer in one tumor. 2021, 49, 3000605211037422	1
288	A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling. 2021, 22,	2
287	Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer. 2021, 13,	0
286	Evaluation of two assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells. 2021, 23, 241-253	0
285	Generation of Antibody-Drug Conjugate Resistant Models. 2021, 13,	0
284	Preclinical tumor organoid models in personalized cancer therapy: Not everyone fits the mold. 2021, 408, 112858	1
283	Gastric Organoids: Progress and Remaining Challenges. 2021, 13, 19-33	0

282	Caveolin-1 and Sox-2 are predictive biomarkers of cetuximab response in head and neck cancer. 2021 , 6,	0
281	Identification of distinct tumor cell populations and key genetic mechanisms through single cell sequencing in hepatoblastoma. 2021 , 4, 1049	2
280	Drug discovery oncology in a mouse: concepts, models and limitations. 2021 , 7, FSO737	1
279	Enhanced chemo-photodynamic therapy of an enzyme-responsive prodrug in bladder cancer patient-derived xenograft models. 2021 , 277, 121061	19
278	Modeling metastasis in mice: a closer look. 2021 , 7, 916-929	3
277	A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia. 2021 , 190, 214-223	0
276	Engineering approaches for studying immune-tumor cell interactions and immunotherapy. 2021 , 24, 101985	14
275	Organoid culture to study epithelial cell differentiation and barrier formation in the colon: bridging the gap between monolayer cell culture and human subject research. 2021 , 57, 174-190	4
274	Self-Activated Cascade-Responsive Sorafenib and USP22 shRNA Co-Delivery System for Synergetic Hepatocellular Carcinoma Therapy. 2021 , 8, 2003042	12
273	Development and characterization of patient-derived xenografts from non-small cell lung cancer brain metastases. 2021 , 11, 2520	4
272	Mouse models of glioblastoma for the evaluation of novel therapeutic strategies. 2021 , 3, vdab100	4
271	Histotripsy Ablation in Preclinical Animal Models of Cancer and Spontaneous Tumors in Veterinary Patients: A Review. 2021 , PP,	0
270	Turmeric Is Therapeutic on Patient-Derived Colorectal Cancer Xenografts: Inhibition of Growth, Metastasis, and Tumor Recurrence. 2020 , 10, 574827	3
269	Isolation of human melanoma stem cells using ALDH as a marker. 2013 , 26, 3.8.1-3.8.10	17
268	Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies. 2014 , 337-372	1
267	Establishment of orthotopic primary cervix cancer xenografts. 2015 , 1249, 381-91	6
266	Orthotopic Model of Ovarian Cancer. 2016 , 1464, 139-149	5
265	Current Perspectives on Nasopharyngeal Carcinoma. 2019 , 1164, 11-34	63

264	Animal Models to Study Cancer and Its Microenvironment. 2020 , 1219, 389-401	12
263	Preclinical Strategies for Testing of Targeted Radiosensitizers. 2020 , 97-114	1
262	Challenges for the Optimization of Drug Therapy in the Treatment of Cancer. 2020 , 163-198	1
261	In Vitro Three-Dimensional Cell Cultures as Tool for Precision Medicine. 2017 , 281-313	3
260	Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts. 2020 , 324, 289-302	34
259	Identification of synergistic drug combinations using breast cancer patient-derived xenografts. 2020 , 10, 1493	19
258	Patient-derived xenografts undergo murine-specific tumor evolution.	3
257	pdxBlacklist: Identifying artefactual variants in patient-derived xenograft samples.	1
256	A clinically and genomically annotated nerve sheath tumor biospecimen repository.	2
255	Induction of pancreatic neoplasia in theKRAS/TP53Oncopig: preliminary report.	4
254	Patient-derived xenograft culture-transplant system for investigation of human breast cancer metastasis.	1
253	Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments.	0
252	Single cell transcriptomics reveals molecular subtype and functional heterogeneity in models of breast cancer.	4
251	A novel xenograft model of human HCC in immunocompetent mouse.	1
250	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.	2
249	Simultaneous extracellular and intracellular quantification of EGFR using paired-agent imaging in an tumor model. 2019 , 10859,	1
248	A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers. 2017 , 2, e89760	49
247	New cast for a new era: preclinical cancer drug development revisited. 2013 , 123, 3639-45	63

246	Patient-derived xenograft (PDX) models: characteristics and points to consider for the process of establishment. 2020 , 33, 153-160	9
245	Erlotinib inhibits growth of a patient-derived chordoma xenograft. 2013 , 8, e78895	31
244	Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts. 2014 , 9, e85308	29
243	Influence of handling conditions on the establishment and propagation of head and neck cancer patient derived xenografts. 2014 , 9, e100995	13
242	Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy. 2014 , 9, e105886	8
241	Integrated analysis of transcriptome in cancer patient-derived xenografts. 2015 , 10, e0124780	7
240	Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas. 2015 , 10, e0124974	17
239	Metformin Treatment Does Not Inhibit Growth of Pancreatic Cancer Patient-Derived Xenografts. 2016 , 11, e0147113	28
238	Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note. 2016 , 11, e0158034	20
237	Short-term spheroid culture of primary colorectal cancer cells as an in vitro model for personalizing cancer medicine. 2017 , 12, e0183074	49
236	Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program. 2017 , 12, e0188228	12
235	Establishment of patient-derived tumor spheroids for non-small cell lung cancer. 2018 , 13, e0194016	27
234	Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits. 2020 , 12, e11889	3
233	Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. 2019 , 26, 765-778	9
232	Mouse models in endocrine tumors. 2018 ,	4
231	Panobinostat suppresses the mesenchymal phenotype in a novel claudin-low triple negative patient-derived breast cancer model. 2018 , 5, 99-108	8
230	Optical imaging of gastric cancer with near-infrared heptamethine carbocyanine fluorescence dyes. 2016 , 7, 57277-57289	30
229	Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation. 2016 , 7, 79292-79304	28

228	Patient-derived glioblastoma stem cells respond differentially to targeted therapies. 2016 , 7, 86406-86419	25
227	Conditionally reprogrammed normal and primary tumor prostate epithelial cells: a novel patient-derived cell model for studies of human prostate cancer. 2017 , 8, 22741-22758	40
226	Melatonin exerts anti-oral cancer effect via suppressing LSD1 in patient-derived tumor xenograft models. 2017 , 8, 33756-33769	23
225	Pancreatic cancer ascites xenograft-an expeditious model mirroring advanced therapeutic resistant disease. 2017 , 8, 40778-40790	18
224	NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. 2017 , 8, 57246-57264	8
223	IL-33 blockade suppresses tumor growth of human lung cancer through direct and indirect pathways in a preclinical model. 2017 , 8, 68571-68582	39
222	Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors. 2017 , 8, 113269-113281	37
221	Inhibition of STAT3 signaling targets both tumor-initiating and differentiated cell populations in prostate cancer. 2014 , 5, 8416-28	46
220	Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisions. 2014 , 5, 9609-18	51
219	An improved method for culturing patient-derived colorectal cancer spheroids. 2018 , 9, 21950-21964	19
218	Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. 2019 , 10, 3924-3930	6
217	Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model. 2015 , 6, 15639-51	29
216	Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development. 2015 , 6, 20160-76	56
215	Acetylation at lysine 71 inactivates superoxide dismutase 1 and sensitizes cancer cells to genotoxic agents. 2015 , 6, 20578-91	12
214	Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma. 2015 , 6, 31323-34	11
213	Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. 2015 , 6, 34561-72	10
212	Validation of a preclinical model for assessment of drug efficacy in melanoma. 2016 , 7, 13069-81	9
211	Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. 2016 , 7, 17087-102	30

210	Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers. 2016 , 7, 20773-87	30
209	The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. 2016 , 7, 28273-85	27
208	A natural small molecule, catechol, induces c-Myc degradation by directly targeting ERK2 in lung cancer. 2016 , 7, 35001-14	22
207	Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic. 2016 , 7, 33529-41	15
206	Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma. 2020 , 3, 572-585	2
205	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 Via Chimeric Antigen Receptor T Cells.	1
204	A Rational Approach to Target the Epidermal Growth Factor Receptor in Glioblastoma. 2017 , 17, 290-296	27
203	Patient-derived Xenografts from Colorectal Carcinoma: A Temporal and Hierarchical Study of Murine Stromal Cell Replacement. 2017 , 37, 3405-3412	22
202	Changing the paradigm: the potential for targeted therapy in laryngeal squamous cell carcinoma. 2016 , 13, 87-100	17
201	Athymic nude mice as an experimental model for cancer treatment. 2016 , 65, S441-S453	49
200	Use of zebrafish embryos as avatar of patients with pancreatic cancer: A new xenotransplantation model towards personalized medicine. 2020 , 26, 2792-2809	12
199	Molecular and clinical implementations of ovarian cancer mouse avatar models. 2015 , 4, 30	8
198	Patient-Derived Xenograft Models of Epithelial Ovarian Cancer for Preclinical Studies. 2017 , 49, 915-926	41
197	Comparison of the Genetic Alterations between Primary Colorectal Cancers and Their Corresponding Patient-Derived Xenograft Tissues. 2018 , 16, 30-35	3
196	A systematic review of the validity of patient derived xenograft (PDX) models: the implications for translational research and personalised medicine. 2018 , 6, e5981	39
195	Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX). 2019 , 7, e6586	3
194	Opportunities and challenges of glioma organoids. 2021 , 19, 102	3
193	Pre-clinical Models of Metastasis in Pancreatic Cancer. 2021 , 9, 748631	2

- 192 Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. **2021**, 13, 6
- 191 BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade. **2021**, 40, 6566-6578 2
- 190 Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. **2021**, 7, eabi7511 3
- 189 Nanotechnology Addressing Cutaneous Melanoma: The Italian Landscape. **2021**, 13, 2
- 188 Preclinical pharmacology modeling of chimeric antigen receptor T therapies. **2021**, 61, 49-61 1
- 187 Translational challenges in pancreatic neuroendocrine tumor immunotherapy. **2021**, 1876, 188640 0
- 186 KIT and KIT Inhibitors. **2013**, 145-174
- 185 Next-Generation Sequencing in the Era of Cancer-Targeted Therapies: Towards the Personalised Medicine. **2015**, 39-55
- 184 Combination Development. **2016**, 151-174
- 183 PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenografts. **2016**, 7, 30977-89 3
- 182 Proteomics for rare cancer. **2017**, 61, 137-140
- 181 Imaging in Neurooncology. **2017**, 689-725
- 180 Chromatin run-on reveals the transcriptional etiology of glioblastoma multiforme. 3
- 179 Obesity and Endometrial Cancer: Mouse Models for Preclinical Prevention Studies. **2018**, 113-135
- 178 Cholesterol Biosynthesis Is a Key Feature of Cancer Stem Cells as Revealed by Proteomic Comparison of Breast Cancer Tissue, Corresponding PDXs and Mammospheres.
- 177 An Overview of Preclinical Mouse Models for Brain Tumors. **2018**, 27, 752-761
- 176 Patient-Derived Xenografts for Research on Hormonal Therapy of Prostate Cancer. **2018**, 19-30
- 175 Unsupervised Gene Identification in Colorectal Cancer. **2019**, 219-227 3

- 174 Bioinformatics workflows for genomic analysis of tumors from Patient Derived Xenografts (PDX): challenges and guidelines. 1
- 173 Small Animal Imaging in Oncology Drug Development. **2019**, 101-115 0
- 172 Preclinical Animal Models for Cancer Research and Drug Discovery. **2019**, 229-254
- 171 From the clinic to the bench and back again in one dog year: identifying new treatments for sarcoma using a cross-species personalized medicine pipeline.
- 170 Application of Peptide Level and Posttranslational Modifications to Integrative Analyses in Proteomics. **2019**, 49-63
- 169 Changes in the Urinary Proteome in a Patient-Derived Xenograft (PDX) Nude Mouse Model of Colorectal Tumor. **2019**, 105-117
- 168 Stromal Barriers Within the Tumor Microenvironment and Obstacles to Nanomedicine. **2019**, 57-89 0
- 167 SELECTED ASPECTS OF ALLO- AND XENOGRRAFT MODEL APPLICATIONS FOR DEVELOPING NOVEL ANTI-CANCER VACCINES AND ONCOLYTIC VIRUSES. **2019**, 21, 221-230 1
- 166 Tissue-guided LASSO for prediction of clinical drug response using preclinical samples.
- 165 Understanding Cancer Phenomenon at Gene Expression Level by using a Shallow Neural Network Chain. **2020**, 281-290
- 164 A model of Zebrafish Avatar for co-clinical trials.
- 163 DNA Microarray Classification: Evolutionary Optimization of Neural Network Hyper-parameters. **2020**, 305-311 1
- 162 Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells. **2020**, 111, 2431-2439 2
- 161 Development and Characterization of Patient-Derived Xenografts from Non-Small Cell Lung Cancer Brain Metastases.
- 160 Modern Approaches to Testing Drug Sensitivity of Patients' Tumors (Review). **2021**, 12, 91-102 0
- 159 Orthotopic Implants in Mice. **2021**, 2226, 215-222
- 158 Tumor Biology Characterization by Imaging in Laboratory. **2020**, 293-323
- 157 Preclinical In Vivo Evaluation of Novel Radiosensitizers by Local Tumor Control Experiments. **2020**, 137-159 0

156	Establishment and characterization of patient-derived primary cell lines as preclinical models for gallbladder carcinoma.. 2020 , 9, 1698-1710	0
155	Conditionally Reprogrammed Cells and Robotic High-Throughput Screening for Precision Cancer Therapy. 2021 , 11, 761986	0
154	Patient-derived xenograft culture-transplant system for investigation of human breast cancer metastasis. 2021 , 4, 1268	1
153	Therapeutic Effects of Dietary Soybean Genistein on Triple-Negative Breast Cancer via Regulation of Epigenetic Mechanisms. 2021 , 13,	0
152	Patient-derived models of brain metastases recapitulate the histopathology and biology of human metastatic cancers.	
151	An Experimental and Computational Protocol to Study Cell Proliferation in Human Acute Myeloid Leukemia Xenografts. 2021 , 2185, 241-258	0
150	Prevention and Therapy of Prostate Cancer: An Update on Alternatives for Treatment and Future Perspectives. 2020 , 15, 168-180	
149	KRAS and PIK3CA mutation frequencies in patient-derived xenograft models of pancreatic and colorectal cancer are reflective of patient tumors and stable across passages. 2014 , 80, 873-7	9
148	Successful establishment of patient-derived tumor xenografts from gastrointestinal stromal tumor-a single center experience. 2016 , 6, 533-43	
147	Bioreactor-Based Tumor Tissue Engineering. 2016 , 8, 44-58	7
146	Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate. 2017 , 56, 166-172	8
145	Anti-tumor efficacy evaluation of a novel monoclonal antibody targeting neutral amino acid transporter ASCT2 using patient-derived xenograft mouse models of gastric cancer. 2017 , 9, 3399-3410	13
144	[Advances in Patient Derived Tumor Xenograft (PDTX) Model from Lung Cancer]. 2017 , 20, 715-719	1
143	The chick chorioallantoic membrane (CAM) as a versatile patient-derived xenograft (PDX) platform for precision medicine and preclinical research. 2018 , 8, 1642-1660	32
142	Gemcitabine induces Epithelial-to-Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma xenografts. 2019 , 11, 765-779	6
141	Establishment of the PDTX model of gynecological tumors. 2019 , 11, 3779-3789	7
140	From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer. 2019 , 9, 2079-2102	4
139	Humanized mice for immune checkpoint blockade in human solid tumors. 2019 , 7, 313-320	6

138	Targeting mitotic exit in solid tumors. 2021 , 11, 3698-3710	
137	Patient-derived xenograft models of neuroendocrine prostate cancer. 2022 , 525, 160-169	1
136	Organoid technology: Current standing and future perspectives. 2021 , 39, 1625-1649	1
135	Prodrug polymeric micelles integrating cancer-associated fibroblasts deactivation and synergistic chemotherapy for gastric cancer. 2021 , 19, 381	2
134	Melanoma Immunotherapy and Precision Medicine in the Era of Tumor Micro-Tissue Engineering: Where Are We Now and Where Are We Going?. 2021 , 13,	
133	Animal Models in Bladder Cancer.. 2021 , 9,	1
132	Patient-Specific Tumor Microenvironment Models. 2021 , 19, 197-222	
131	Approaches for Head and Neck cancer research - current status and the way forward. 2021 , 1-49	
130	Deciphering intratumoral heterogeneity using integrated clonal tracking and single-cell transcriptome analyses. 2021 , 12, 6522	2
129	The HROC-Xenobank-A High Quality Assured PDX Biobank of >100 Individual Colorectal Cancer Models. 2021 , 13,	1
128	The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval. 2021 , 10,	4
127	The distinct responsiveness of cytokeratin 19-positive hepatocellular carcinoma to regorafenib. 2021 , 12, 1084	1
126	Stem Cell Based Preclinical Drug Development and Toxicity Prediction. 2021 , 27, 2237-2251	0
125	Development of biomaterials for constructing tumor microenvironment in vitro models. 2021 , 36, 256-264	
124	Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model.. 2022 , 2022, 1987705	0
123	Patient-derived xenograft models in hepatopancreatobiliary cancer.. 2022 , 22, 41	4
122	Probabilistic Learning of Treatment Trees in Cancer.	
121	Salivary gland cancer in the setting of tumor microenvironment: Translational routes for therapy.. 2022 , 103605	0

120	Functional Therapeutic Target Validation Using Pediatric Zebrafish Xenograft Models.. 2022 , 14,	3
119	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts.. 2022 , 6, e2100242	0
118	Predicting response to neoadjuvant chemoradiotherapy in rectal cancer: from biomarkers to tumor models.. 2022 , 14, 17588359221077972	2
117	The OncoLoop Network-based Precision Cancer Medicine Framework.	1
116	Current applications and future perspective of CRISPR/Cas9 gene editing in cancer.. 2022 , 21, 57	7
115	Opportunities and challenges of patient-derived models in cancer research: patient-derived xenografts, patient-derived organoid and patient-derived cells.. 2022 , 20, 37	1
114	Use of Patient-Derived Organoids as a Treatment Selection Model for Colorectal Cancer: A Narrative Review.. 2022 , 14,	1
113	Serine-Threonine Kinase Receptor Associate Protein (STRAP) confers an aggressive phenotype in neuroblastoma via regulation of Focal Adhesion Kinase (FAK).. 2022 ,	0
112	A Systematic Comparative Assessment of the Response of Ovarian Cancer Cells to the Chemotherapeutic Cisplatin in 3D Models of Various Structural and Biochemical Configurations-Does One Model Type Fit All?. 2022 , 14,	1
111	Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells.. 2022 , 13, 1624	1
110	How to Improve SBRT Outcomes in NSCLC: From Pre-Clinical Modeling to Successful Clinical Translation.. 2022 , 14,	0
109	Proteomic and Transcriptomic Profiling Reveals Mitochondrial Oxidative Phosphorylation as Therapeutic Vulnerability in Androgen Receptor Pathway Active Prostate Tumors.. 2022 , 14,	1
108	Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer.. 2022 ,	0
107	Genomic and Molecular Signatures of Successful Patient-Derived Xenografts for Oral Cavity Squamous Cell Carcinoma.. 2022 , 12, 792297	0
106	Subclonal heterogeneity and evolution in breast cancer.. 2021 , 7, 155	3
105	Comparative study on the efficacy and exposure of molecular target agents in non-small cell lung cancer PDX models with driver genetic alterations.. 2021 ,	0
104	Establishment of Sunitinib-Resistant Xenograft Model of Renal Cell Carcinoma and the Identification of Drug-Resistant Hub Genes and Pathways.. 2021 , 15, 5061-5074	2
103	Mouse characteristics that affect establishing xenografts from hepatocellular carcinoma patient biopsies in the United States.. 2021 ,	1

102	GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers.. 2022 , 5, 373	0
101	Image_1.TIF. 2020 ,	
100	Image_2.TIF. 2020 ,	
99	Image_3.TIF. 2020 ,	
98	Image_1.JPEG. 2020 ,	
97	Image_2.JPEG. 2020 ,	
96	Table_1.XLSX. 2020 ,	
95	Data_Sheet_1.docx. 2019 ,	
94	An association between successful engraftment of osteosarcoma patient-derived xenografts and clinicopathological findings. 2020 , 35, 1295-1307	1
93	Development and immunohistochemical characterization of patient-derived xenograft models for muscle invasive bladder cancer.. 2021 , 24, 1650-1655	
92	5-arylalkynyl-2-benzoyl thiophene: a novel microtubule inhibitor exhibits antitumor activity without neurological toxicity.. 2022 , 12, 229-246	
91	Dissecting the Genome for Drug Response Prediction.. 2022 , 2449, 187-196	0
90	Tumor organoids: applications in cancer modeling and potentials in precision medicine.. 2022 , 15, 58	3
89	Patient-derived models of brain metastases recapitulate human disseminated disease.. 2022 , 3, 100623	0
88	Development of patient derived organoids for cancer drug screening applications.. 2022 , 124, 151895	0
87	Tumor Purity in Preclinical Mouse Tumor Models. 2022 , 2, 353-365	0
86	Spatially resolved cell tagging and surfaceome labeling via targeted photocatalytic decaging. 2022 ,	3
85	Patient-derived xenograft (PDX) models, applications and challenges in cancer research.. 2022 , 20, 206	5

84	Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up.. 2022 , 10,	0
83	Construction of gastric cancer patient-derived organoids and their utilization in a comparative study of clinically used paclitaxel nanoformulations.. 2022 , 20, 233	0
82	Genomic Validation of Endometrial Cancer Patient-Derived Xenograft Models as a Preclinical Tool. 2022 , 23, 6266	1
81	Bioengineered RNA Therapy in Patient-Derived Organoids and Xenograft Mouse Models. 2022 , 191-206	
80	Breast Cancer Xenograft Murine Models. 2022 , 31-44	
79	In Vivo Modeling of Human Breast Cancer Using Cell Line and Patient-Derived Xenografts.	0
78	Assessing the performance of different outcomes for tumor growth studies with animal models.	
77	Personalized Drug Screening for Functional Tumor Profiling. 2022 ,	0
76	Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities. 2022 , 329-344	
75	Organoid systems for recapitulating the intestinal stem cell niche and modeling disease in vitro. 2022 , 57-96	1
74	A Multicentre Clinical Study of Sarcoma Personalised Treatment Using Patient-Derived Tumour Xenografts. 2022 ,	0
73	Translational and Clinical Relevance of PDX-Derived Organoid Models in Oncology Drug Discovery and Development. 2022 , 2,	
72	A novel method for the isolation of CD45-positive and CD45-negative cells from malignant pleural effusion. 1, e13	
71	Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.	0
70	NIR-II fluorescence/photoacoustic imaging of ovarian cancer and peritoneal metastasis.	2
69	Evaluating Translational Methods for Personalized Medicine – Scoping Review. 2022 , 12, 1177	1
68	The cell-line-derived subcutaneous tumor model in preclinical cancer research.	0
67	?????????????. 2022 ,	0

- 66 Patient-derived cancer models: Valuable platforms for anticancer drug testing. 12,
- 65 A high-quality severe combined immunodeficiency (SCID) rat bioresource. **2022**, 17, e0272950 ○
- 64 Mouse Tumor Homografts Recapitulate Human Molecular Pathogenesis. **2022**, 75-106
- 63 Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors. **2022**, 41, 1
- 62 The application of zebrafish patient-derived xenograft tumor models in the development of antitumor agents. ○
- 61 Characterisation of a Novel Cell Line (ICR-SS-1) Established from a Patient-Derived Xenograft of Synovial Sarcoma. **2022**, 11, 2418 ○
- 60 Pre-Training on In Vitro and Fine-Tuning on Patient-Derived Data Improves Deep Neural Networks for Anti-Cancer Drug-Sensitivity Prediction. **2022**, 14, 3950 ○
- 59 Complex in vitro 3D models of digestive system tumors to advance precision medicine and drug testing: Progress, challenges, and trends. **2022**, 239, 108276 ○
- 58 Stimulus-responsive inorganic semiconductor nanomaterials for tumor-specific theranostics. **2022**, 473, 214821 ○
- 57 Chorioallantoic Membrane (CAM) and In'Ovo Models as Potential Platforms for Testing Cancer Agents. **2022**, 1-26 ○
- 56 Animal Models for Small Cell Lung Cancer Research: Current Status and Future Perspectives. **2022**, 1-18 ○
- 55 Orthotopic PDX and CDX Mice Model for Cancer Stem Cell Research. **2022**, 1-24 ○
- 54 Animal Models in Cancer Research: Breast Cancer. **2022**, 1-20 ○
- 53 Zebrafish Models of Paediatric Brain Tumours. **2022**, 23, 9920 ○
- 52 A Three-Dimensional Organoid Culture System to Model Invasive Patterns of Patient-Derived Glioma Stem Cells. **2023**, 139-158 ○
- 51 The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma. **2022**, 13, ○
- 50 Establishment and characterization of NCC-PS1-C1: a novel cell line of pleomorphic sarcoma from a patient after neoadjuvant radiotherapy. **2022**, 35, 2011-2019 ○
- 49 Patient-derived tumor organoids predict responses to irinotecan-based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. 1

- 48 Sabizabulin, a Potent Orally Bioavailable Colchicine Binding Site Agent, Suppresses HER2+ Breast Cancer and Metastasis. **2022**, 14, 5336 ○
- 47 A pan-cancer PDX histology image repository with genomic and pathological annotations for deep learning analysis. ○
- 46 Review on Advanced Cancer Modeling for a Cancer Study. **2022**, 44, 5352-5362 ○
- 45 MNX1-AS1 promotes phase separation of IGF2BP1 to drive c-Myc-mediated cell cycle progression and proliferation in lung cancer. ○
- 44 Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models. **2022**, 1 ○
- 43 STAT3/miR-130b-3p/MBNL1 feedback loop regulated by mTORC1 signaling promotes angiogenesis and tumor growth. **2022**, 41, ○
- 42 Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in NonSmall Cell Lung Cancer. OF1-OF15 ○
- 41 Microfluidic vascular models of tumor cell extravasation. 12, ○
- 40 Porous Paclitaxel Mesh Reduces Local Recurrence in Patient-Derived Xenograft Resection Model. **2022**, ○
- 39 A novel xenograft model of human hepatocellular carcinoma in immunocompetent mice based on the microcarrier-6. **2022**, 101738 ○
- 38 OncoLoop: A network-based precision cancer medicine framework. ○
- 37 Modeling Cutaneous Squamous Cell Carcinoma for Laboratory Research. ○
- 36 Assessment of stromal SCD-induced drug resistance of PDAC using 3D-printed zPDX model chips. **2023**, 26, 105723 ○
- 35 Deep tumor-penetrating nano-delivery strategy to improve diagnosis and therapy in patient-derived xenograft (PDX) oral cancer model and patient tissue. ○
- 34 Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic. **2022**, 11, 3868 ○
- 33 Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma. ○
- 32 Advancing intestinal organoid technology to decipher nano-intestine interactions and treat intestinal disease. ○
- 31 Animal Models for Bone Metastatic Prostate Cancer. **2022**, 20, 248-256 ○

- 30 Patient-derived xenograft model in colorectal cancer basic and translational research. ○
- 29 Role of Patient-Derived Models of Cancer in Translational Oncology. **2023**, 15, 139 ○
- 28 Unraveling Plasma Protein Corona by Ultrasonic Cavitation Augments Active-Transporting of Liposome in Solid Tumor. 2207271 ○
- 27 Recent advances in microfluidic-based cancer immunotherapy-on-a-chip strategies. **2023**, 17, 011501 ○
- 26 Papillary thyroid cancer organoids harboring BRAFV600E mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies. **2023**, 21, 1 ○
- 25 Spotlight on P2X7 Receptor PET Imaging: A Bright Target or a Failing Star?. **2023**, 24, 1374 ○
- 24 Cryopreservation of tissues by slow-freezing using an emerging zwitterionic cryoprotectant. **2023**, 13, ○
- 23 A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology. **2023**, 18, e0279821 1
- 22 Establishment and characterization of NCC-DSM1-C1: a novel cell line derived from a patient with desmoid fibromatosis. ○
- 21 Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig. **2023**, 16, ○
- 20 Chromatin mutations in pediatric high grade gliomas. 12, ○
- 19 Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer. **2023**, 23, ○
- 18 Animal Models for Small Cell Lung Cancer Research: Current Status and Future Perspectives. **2023**, 527-544 ○
- 17 Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research. **2023**, 15, 588 ○
- 16 Animal Models in Cancer Research: Breast Cancer. **2023**, 247-266 ○
- 15 Orthotopic PDX and CDX Mice Model for Cancer Stem Cell Research. **2023**, 503-526 ○
- 14 3D Culturing of Stem Cells: An Emerging Technique for Advancing Fundamental Research in Regenerative Medicine. ○
- 13 Identification and characterization of a proliferative cell population in estrogen receptor-positive metastatic breast cancer through spatial and single-cell transcriptomics. ○

- 12 Chorioallantoic Membrane (CAM) and In'Ovo Models as Potential Platforms for Testing Cancer Agents. **2023**, 457-483 ○
- 11 Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft. ○
- 10 Pediatric Patient-Derived-Xenograft development in MAPPYACTS International pediatric cancer precision medicine trial in relapsed and refractory tumors. ○
- 9 Chick Chorioallantoic Membrane as a Patient-Derived Xenograft Model for Uveal Melanoma: Imaging Modalities for Growth and Vascular Evaluation. **2023**, 15, 1436 ○
- 8 Personalized Oncology by In Vivo Chemical Imaging: Photoacoustic Mapping of Tumor Oxygen Predicts Radiotherapy Efficacy. **2023**, 17, 4396-4403 ○
- 7 Patient-derived models: Promising tools for accelerating the clinical translation of breast cancer research findings. **2023**, 425, 113538 ○
- 6 Experimental mouse models for translational human cancer research. 14, ○
- 5 Application status and future prospects of the PDX model in lung cancer. 13, ○
- 4 Allyl isothiocyanate suppressed the proliferation of oral squamous cell carcinoma in vitro, in vivo, and in patient-derived tumor xenografts by downregulating the KDM8/CCNA1 axis. ○
- 3 Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma. ○
- 2 HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models. **2023**, 13, ○
- 1 Patient-derived xenografts or organoids in the discovery of traditional and self-assembled drug for tumor immunotherapy. 13, ○